Pyclen ligand, pyclen complex and preparation method therefor and use thereof
By designing Pyclen ligands and complexes, the problem of insufficient stability of gadolinium-based magnetic resonance imaging contrast agents has been solved, resulting in a more stable and safer magnetic resonance imaging contrast agent, which shows excellent imaging effects, especially in hepatobiliary imaging.
Patent Information
- Application Number
- PCT/CN2024/093901
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
The stability issues of existing gadolinium-based magnetic resonance contrast agents (GBCAs) pose safety risks, necessitating the development of more stable and safer alternatives.
We designed and synthesized Pyclen ligands and their complexes, and improved their stability by introducing specific groups to form contrast agents suitable for magnetic resonance imaging.
It improves the stability and safety of magnetic resonance imaging contrast agents, enhances liver and gallbladder imaging capabilities, and demonstrates superior imaging effects compared to traditional gadoteric acid.
Smart Images

Figure CN2024093901_21112024_PF_FP_ABST
Abstract
Description
Pyclen ligand, Pyclen complex, preparation method and application
[0001] This application claims priority to a Chinese patent application filed with the Patent Office of China on May 18, 2023, with application number CN202310571344.7 and invention name “Pyclen ligand, Pyclen complex, preparation method and application”, the entire contents of which are incorporated herein by reference. Technical Field
[0002] The present invention relates to the technical field of organic complexes, in particular to a Pyclen ligand, a Pyclen complex, a preparation method and an application thereof. Background Art
[0003] Magnetic resonance imaging (MRI) is a commonly used noninvasive diagnostic technique in clinical practice, offering unparalleled advantages over other diagnostic techniques in soft tissue and neurological imaging. While this imaging technique is harmless to the human body, due to its low sensitivity, gadolinium (Gd)-based contrast agents (GBCAs) are commonly used in over 40% of MRI examinations. However, in recent years, safety concerns related to the stability of GBCAs have drawn close attention from agencies such as the China Food and Drug Administration (CFDA) and the U.S. Food and Drug Administration (FDA).
[0004] One way to address the safety of GBCAs is to improve the stability of GBCAs and reduce the release of free Gd(III) ions; the second is to develop safer and more reliable alternatives to GBCAs.
[0005] Summary of the Invention
[0006] The purpose of the present invention is to provide a Pyclen ligand, a Pyclen complex, and a preparation method and application thereof. The Pyclen complex formed based on the Pyclen ligand provided by the present invention has good stability and is suitable for preparing a magnetic resonance imaging contrast agent.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides a Pyclen ligand having a structure shown in any one of formulas i to vi:
[0009] R in the formulas i to vi 1 and R 2 are independently -H, C1-C4 alkyl, -CH2OH, -CH(CH3)OH, -CH2CH2OH, -(CH2)3NH2 or -(CH2) n Ph, n=1 to 4;
[0010] R' in the formulas i to iii is -H, Said X is -CH2-, -NH- or -O-, said m=1 to 10;
[0011] R″ in the formulas i to vi is -H, halogen, -COOH, -NO2, -CF3, -C(CH3)3, -Ph or -OBn;
[0012] R'' in the formulae iv to vi is -H, halogen, -COOH, -NO2, -CF3, -C(CH3)3, -Ph or -OBn.
[0013] Preferably, the C1-C4 alkyl group is -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3 or -CH2CH2CH2CH3.
[0014] Preferably, R in the formulas i to vi 1 and R 2 are -CH3, -CH2CH3 or -CH(CH3)2; or R 1 is -CH3 and R 2 It is -CH(CH3)2.
[0015] Preferably, the for
[0016] Preferably, the Pyclen ligand is any one of the following compounds:
[0017] The present invention provides a method for preparing the Pyclen ligand described in the above technical solution.
[0018] (1-1) When R′ in formula (i) is -H, the preparation method of the Pyclen ligand having the structure shown in formula (i) comprises the following steps:
[0019] Compound a, tert-butyl bromoacetate, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound a-1;
[0020] The compound a-1 is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula I;
[0021] The structural formulas of compound a and compound a-1 are shown below:
[0022] The R 1 、R 2and R″ are as defined in formula i;
[0023] (1-2) When R′ in formula (i) is not -H, the method for preparing a Pyclen ligand having the structure shown in formula (i) comprises the following steps:
[0024] Compound b, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound b-1;
[0025] The compound b-1, lithium hydroxide, methanol and water are mixed and hydrolyzed to obtain a Pyclen ligand having a structure shown in formula i. The structural formulas of the compound b and compound b-1 are shown below in sequence:
[0026] The R 1 、R 2 , R′ and R″ are as defined in formula i;
[0027] (2-1) When R′ in formula ii is not -H, the preparation method of the Pyclen ligand having the structure shown in formula ii comprises the following steps:
[0028] Compound c, R′-Br, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound c-1;
[0029] The compound c-1 is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula ii;
[0030] The structural formulas of compound c and compound c-1 are shown below:
[0031] The R 1 、R 2 , R′ and R″ are as defined in formula ii;
[0032] (2-2) When R′ in formula ii is -H, the preparation method of the Pyclen ligand having the structure shown in formula ii comprises the following steps:
[0033] Compound C is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula II;
[0034] (3-1) When R′ in formula iii is not -H, the preparation method of the Pyclen ligand having the structure shown in formula iii comprises the following steps:
[0035] Compound d, R′-Br, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound d-1;
[0036] Mixing the compound d-1, lithium hydroxide, methanol and water to perform a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula III;
[0037] The structural formulas of compound d and compound d-1 are shown below:
[0038] The R 1 、R 2 , R′ and R″ are as defined in formula iii;
[0039] (3-2) When R′ in formula iii is -H, the preparation method of the Pyclen ligand having the structure shown in formula iii comprises the following steps:
[0040] Compound d, lithium hydroxide, methanol and water are mixed and hydrolyzed to obtain a Pyclen ligand having a structure shown in Formula iii;
[0041] (4) A method for preparing a Pyclen ligand having a structure shown in Formula IV, comprising the following steps:
[0042] Compound a, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound a-2;
[0043] Mixing the compound a-2 with trifluoroacetic acid and performing a deprotection reaction to obtain compound a-3;
[0044] The compound a-3, compound a-4, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound a-5;
[0045] The compound a-5, lithium hydroxide, methanol and water are mixed to carry out a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula IV;
[0046] The structural formulas of compound a-2, compound a-3, compound a-4 and compound a-5 are shown below:
[0047] The R 1 、R 2 , R″ and R″′ are as defined in formula iv;
[0048] (5) A method for preparing a Pyclen ligand having a structure shown in Formula V, comprising the following steps:
[0049] Compound c, compound a-4, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound c-2;
[0050] Mixing the compound c-2 with trifluoroacetic acid to carry out a first-stage hydrolysis reaction to obtain a hydrolysis intermediate;
[0051] The hydrolysis intermediate, lithium hydroxide, methanol and water are mixed to carry out a second-stage hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula V;
[0052] The structural formula of the compound c-2 is shown below:
[0053] The R 1 、R 2 , R″ and R″′ are as defined in formula v;
[0054] (6) A method for preparing a Pyclen ligand having a structure shown in Formula VI, comprising the following steps:
[0055] Compound d, compound a-4, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound d-2;
[0056] Mixing the compound d-2, lithium hydroxide, methanol and water to carry out a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula VI;
[0057] The structural formula of the compound d-2 is shown below:
[0058] The R 1 、R 2 , R″ and R″′ are as defined in formula vi.
[0059] Preferably, the temperature of the nucleophilic substitution reaction in (1-1) is 45-55°C, and the time is 10-15 hours; the temperature of the hydrolysis reaction is 85-95°C.
[0060] Preferably, the temperature of the nucleophilic substitution reaction in (1-2) is 45-55° C., and the time is 10-15 h; the temperature of the hydrolysis reaction is 15-35° C., and the time is 10-15 h.
[0061] Preferably, the temperature of the nucleophilic substitution reaction in (2-1) is 45-55°C, and the time is 10-15 hours; the temperature of the hydrolysis reaction is 85-95°C.
[0062] Preferably, the temperature of the hydrolysis reaction in (2-2) is 85-95°C.
[0063] Preferably, the temperature of the nucleophilic substitution reaction in (3-1) is 45-55° C., and the time is 10-15 h; the temperature of the hydrolysis reaction is 15-35° C., and the time is 10-15 h.
[0064] Preferably, the temperature of the hydrolysis reaction in (3-2) is 15 to 35° C., and the time is 10 to 15 hours.
[0065] Preferably, the temperature of the nucleophilic substitution reaction in preparing compound a-2 in (4) is 45-55°C, and the time is 10-15 h; the temperature of the deprotection reaction is 85-95°C; the temperature of the nucleophilic substitution reaction in preparing compound a-5 is 45-55°C, and the time is 10-15 h; the temperature of the hydrolysis reaction is 15-35°C, and the time is 10-15 h.
[0066] Preferably, the temperature of the nucleophilic substitution reaction in (5) is 45-55°C, and the time is 10-15 hours; the temperature of the first-stage hydrolysis reaction is 85-95°C; and the temperature of the second-stage hydrolysis reaction is 15-35°C, and the time is 10-15 hours.
[0067] Preferably, the temperature of the nucleophilic substitution reaction in (6) is 45-55° C., and the time is 10-15 h; the temperature of the hydrolysis reaction is 15-35° C., and the time is 10-15 h.
[0068] The present invention provides a Pyclen complex having a structure shown in any one of Formulas I to VI:
[0069] R in the formulas I to VI 1 and R 2 , R′ in formulas I to III, R″ in formulas I to VI, and R″′ in formulas IV to VI are as defined in the above technical solutions;
[0070] In the formulas I to III, M1 is Mn(II), Fe(III), Co(II), Cu(II) or Ni(II);
[0071] In the formulas IV to VI, M2 is a lanthanide metal ion.
[0072] Preferably, M2 is Gd(III), Eu(III), Tb(III) or Yb(III).
[0073] Preferably, the Pyclen complex is any one of the following compounds:
[0074] The present invention provides a method for preparing the Pyclen complex described in the above technical solution, comprising the following steps:
[0075] A pyclen ligand, a soluble metal salt and water are mixed to carry out a complexation reaction to obtain a pyclen complex having a structure shown in any one of formulas I to VI; the pyclen ligand is the pyclen ligand described in the above technical solution; and the metal ion in the soluble metal salt is M1 or M2.
[0076] Preferably, the soluble metal salt is a hydrochloride.
[0077] Preferably, the hydrochloride is FeCl3, NiCl2, CuCl2·2H2O, CoCl2·6H2O, MnCl2·4H2O, GdCl3·6H2O, EuCl3·6H2O, YbCl3·6H2O or TbCl3·6H2O.
[0078] Preferably, when the Pyclen ligand is a compound represented by formula i to iii, the temperature of the complexation reaction is room temperature and the time is 8 to 24 hours; when the Pyclen ligand is a compound represented by formula iv to vi, the temperature of the complexation reaction is 90 to 110° C. and the time is 8 to 24 hours.
[0079] The present invention provides a pharmaceutical composition comprising the Pyclen complex described in the above technical solution and a pharmaceutically acceptable carrier.
[0080] The present invention provides the use of the Pyclen complex described in the above technical solution or the pharmaceutical composition described in the above technical solution in the preparation of a magnetic resonance imaging contrast agent.
[0081] Preferably, the magnetic resonance imaging contrast agent is a hepatobiliary-targeted magnetic resonance imaging contrast agent.
[0082] The present invention provides a magnetic resonance imaging contrast agent, comprising the Pyclen complex described in the above technical solution or the pharmaceutical composition described in the above technical solution.
[0083] The present invention provides a pyclen ligand. The pyclen ligand provided by the present invention uses a 1,4,7,10-tetraaza-2,6-pyridine cyclophane (pyclen) ring structure as a parent ring. The pyridine group in this parent ring structure has certain limitations on the rigidity of the macrocyclic backbone. Introducing a chiral group R into the parent ring further enhances the rigidity of the ring structure. Using this ligand as a ligand is beneficial for improving the stability of the resulting pyclen complex.
[0084] Specifically, the introduction of a lipophilic group R' into the Pyclen ligands represented by Formulas i to iii can increase the distribution of the Pyclen complex (with M1 as the central ion, a hexacoordinated Pyclen complex) in the hepatobiliary when used as a contrast agent, thereby enhancing its hepatobiliary imaging ability and enabling its use as a hepatobiliary-targeted MRI contrast agent. Furthermore, the introduction of a group R" onto the pyridine of the Pyclen ring can increase the diversity of Pyclen complex modifications, such as altering the solubility and metabolic properties of the complex. Test results show that the Pyclen complexes formed by the Pyclen ligands represented by Formulas i to iii and Mn(II) exhibit extremely strong binding ability with HSA, have certain hepatobiliary targeting ability, and demonstrate good imaging effects in MRI imaging of subcutaneous tumor-bearing mice, with imaging capabilities comparable to or superior to those of gadoteric acid (Gd-DOTA).
[0085] In the pyclen ligands shown in formulas iv-vi, the introduction of an R" group on the pyridine of the pyclen ring and an R"' group on the sidearm pyridine can increase the diversity of the modification of the pyclen complex (octacoordinate pyclen complex with M2 as the central ion), such as changing the solubility and metabolic properties of the complex. The results of the examples show that the pyclen complexes formed by the pyclen ligands shown in formulas iv-vi and Gd(III) have high stability and a half-life significantly longer than that of gadoteric acid (Gd-DOTA). BRIEF DESCRIPTION OF THE DRAWINGS
[0086] FIG1 is the ultraviolet absorption spectrum and fluorescence emission spectrum of the complex EuL10 prepared in Example 13;
[0087] FIG2 is the ultraviolet absorption spectrum and fluorescence emission spectrum of the complex EuL11 prepared in Example 16;
[0088] FIG3 is an image of the complex MnL1 prepared in Example 1 as an MRI contrast agent for imaging subcutaneous tumor mice;
[0089] FIG4 is an image of the complex MnL2 prepared in Example 2 used as an MRI contrast agent for imaging subcutaneous tumor mice;
[0090] FIG5 is a diagram of the complex MnL4 prepared in Example 4 used as an MRI contrast agent for hepatobiliary imaging in mice;
[0091] FIG6 is a diagram showing the complex MnL5 prepared in Example 5 used as an MRI contrast agent for hepatobiliary imaging in mice;
[0092] FIG7 is an image of the complex GdL10 prepared in Example 10 used as an MRI contrast agent for imaging subcutaneous tumor-bearing mice;
[0093] FIG8 is an image of the complex MnL13 prepared in Example 27 used as an MRI contrast agent for imaging subcutaneous tumor-bearing mice;
[0094] FIG9 is an image of the complex MnL14 prepared in Example 28 used as an MRI contrast agent for imaging subcutaneous tumor-bearing mice;
[0095] FIG10 is an image of the complex MnL15 prepared in Example 29 used as an MRI contrast agent for imaging subcutaneous tumor-bearing mice;
[0096] FIG11 is an imaging diagram of the complex MnL17 prepared in Example 31 used as an MRI contrast agent in mice bearing subcutaneous tumors. DETAILED DESCRIPTION
[0097] The present invention provides a Pyclen ligand having a structure shown in any one of formulas i to vi:
[0098] R in the formulas i to vi 1 and R 2 are independently -H, C1-C4 alkyl, -CH2OH, -CH(CH3)OH, -CH2CH2OH, -(CH2)3NH2 or -(CH2) n Ph, n=1 to 4;
[0099] R' in the formulas i to iii is -H, Said X is -CH2-, -NH- or -O-, said m=1 to 10;
[0100] R″ in the formulas i to vi is -H, halogen, -COOH, -NO2, -CF3, -C(CH3)3, -Ph or -OBn;
[0101] R'' in the formulae iv to vi is -H, halogen, -COOH, -NO2, -CF3, -C(CH3)3, -Ph or -OBn.
[0102] In the present invention, specifically, the R 1 and R 2 It can be the same or different.
[0103] In the present invention, the C1 to C4 alkyl group is preferably -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3 or -CH2CH2CH2CH3; the -(CH2) n In Ph, n is preferably 2 to 3. In the present invention, specifically, R 1 and R 2Preferably, they are -CH3, -CH2CH3 or -CH(CH3)2; or R 1 is -CH3 and R 2 It is -CH(CH3)2.
[0104] In the present invention, m is preferably 1-6, more preferably 1-3.
[0105] In the present invention, specifically, R' in the formulas i to iii is preferably -H,
[0106] In the present invention, R″ in the formulae i to vi is preferably -H.
[0107] In the present invention, R'' in the formulae iv to vi is preferably -H.
[0108] In the present invention, the Pyclen ligand is preferably any one of the following compounds:
[0109] The present invention provides methods for preparing the Pyclen ligand described in the above technical solution. Specifically, different preparation methods are employed depending on the structure of the Pyclen ligand, as described in detail below. Unless otherwise specified, all raw materials used in the present invention are commercially available products well known to those skilled in the art or are prepared using methods well known to those skilled in the art.
[0110] In the present invention, when R′ in formula (i) is -H, the preparation method of the Pyclen ligand having the structure shown in formula (i) comprises the following steps:
[0111] Compound a, tert-butyl bromoacetate, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound a-1;
[0112] The compound a-1 is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula I;
[0113] The structural formulas of compound a and compound a-1 are shown below:
[0114] The R 1 、R 2 and R″ are as defined in formula i.
[0115] In the present invention, when R' in formula i is -H, the reaction formula for preparing the Pyclen ligand having the structure shown in formula i is as follows:
[0116] In the present invention, compound a, tert-butyl bromoacetate, potassium carbonate, and acetonitrile are mixed and subjected to a nucleophilic substitution reaction (referred to as the first nucleophilic substitution reaction) to obtain compound a-1. In the present invention, the molar ratio of compound a, tert-butyl bromoacetate, and potassium carbonate is preferably 1:4.5-5.5:9-11, more preferably 1:5:10. Acetonitrile is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, compound a is preferably dissolved in acetonitrile, followed by the addition of potassium carbonate and tert-butyl bromoacetate to carry out the first nucleophilic substitution reaction. In the present invention, the temperature for the first nucleophilic substitution reaction is preferably 45-55°C, more preferably 50°C, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the first nucleophilic substitution reaction, the resulting product is preferably filtered to remove insoluble solids, the solvent is evaporated from the filtrate under reduced pressure, and the residue is purified by column chromatography (preferably using a 5:1 volume ratio of dichloromethane to methanol as the eluent) to obtain compound a-1.
[0117] After obtaining compound a-1, the present invention mixes the compound a-1 with trifluoroacetic acid and performs a hydrolysis reaction (referred to as the first hydrolysis reaction) to obtain a Pyclen ligand having a structure shown in formula i. In the present invention, the amount ratio of the compound a-1 to trifluoroacetic acid is preferably 1 mmol: 8 to 12 mL, more preferably 1 mmol: 10 mL. In the present invention, the temperature of the first hydrolysis reaction is preferably 85 to 95°C, more preferably 90°C; the time of the first hydrolysis reaction is based on ensuring that the compound a-1 is completely hydrolyzed, and specifically, HPLC can be used to monitor the reaction. After the first hydrolysis reaction, the present invention preferably evaporates the solvent from the obtained product system under reduced pressure, dissolves the residue in water, separates it using semi-preparative HPLC, combines the separated liquid phases, removes acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water under reduced pressure, and freeze-dries the remaining liquid to obtain a Pyclen ligand having a structure shown in formula i.
[0118] In the present invention, when R′ in formula (i) is not -H, the preparation method of the Pyclen ligand having the structure shown in formula (i) comprises the following steps:
[0119] Compound b, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound b-1;
[0120] Mixing the compound b-1, lithium hydroxide, methanol and water to perform a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula I;
[0121] The structural formulas of compound b and compound b-1 are shown below:
[0122] The R 1 、R 2, R′ and R″ are as defined in formula i.
[0123] In the present invention, when R′ in formula i is not -H, the reaction formula for preparing the Pyclen ligand having the structure shown in formula i is as follows:
[0124] In the present invention, compound b, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to perform a nucleophilic substitution reaction (referred to as the second nucleophilic substitution reaction) to obtain compound b-1. In the present invention, the raw material ratio, reaction conditions and post-treatment method used in the second nucleophilic substitution reaction are preferably the same as those of the first nucleophilic substitution reaction and are not further described here.
[0125] After obtaining compound b-1, the present invention mixes the compound b-1, lithium hydroxide, methanol and water to carry out a hydrolysis reaction (referred to as the second hydrolysis reaction) to obtain a Pyclen ligand having a structure shown in formula i. In the present invention, the molar ratio of the compound b-1 to lithium hydroxide is preferably 1:3.5-4.5, more preferably 1:4; the volume ratio of the methanol to water is preferably 1:0.8-1.2, more preferably 1:1, and the methanol and water are used as solvents in an amount that ensures the smooth progress of the reaction. The present invention preferably dissolves compound b-1 in methanol, and then adds an aqueous solution of lithium hydroxide to carry out a second hydrolysis reaction. In the present invention, the temperature of the second hydrolysis reaction is preferably 15-35°C, more preferably room temperature; the time is preferably 10-15h, more preferably 12h. After the second hydrolysis reaction, the present invention preferably adjusts the pH value of the resulting product system to 6 with dilute hydrochloric acid (preferably at a concentration of 1.0 mol / L), separates it using semi-preparative HPLC, combines the separated liquid phases, removes acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water under reduced pressure, and freeze-dries the remaining liquid to obtain a Pyclen ligand having a structure shown in Formula I.
[0126] In the present invention, when R′ in formula ii is not -H, the preparation method of the Pyclen ligand having the structure shown in formula ii comprises the following steps:
[0127] Compound c, R′-Br, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound c-1;
[0128] The compound c-1 is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula ii;
[0129] The structural formulas of compound c and compound c-1 are shown below:
[0130] The R 1 、R 2, R′ and R″ are as defined in formula ii.
[0131] In the present invention, when R′ in formula ii is not -H, the reaction formula for preparing the Pyclen ligand having the structure shown in formula ii is as follows:
[0132] In the present invention, compound c, R'-Br, potassium carbonate, and acetonitrile are mixed and subjected to a nucleophilic substitution reaction (referred to as the third nucleophilic substitution reaction) to obtain compound c-1. In the present invention, the molar ratio of compound c, R'-Br, and potassium carbonate is preferably 1:1.3-1.7:1.8-2.2, more preferably 1:1.5:2. The acetonitrile is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, compound a is preferably dissolved in acetonitrile, followed by the addition of potassium carbonate and R'-Br to carry out the third nucleophilic substitution reaction. In the present invention, the temperature of the third nucleophilic substitution reaction is preferably 45-55°C, more preferably 50°C, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the third nucleophilic substitution reaction, the resulting product system is preferably filtered to remove solid insolubles, the filtrate is evaporated under reduced pressure to remove the solvent, and the residue is purified by column chromatography (preferably using an eluent of dichloromethane:methanol = 5:1 by volume) to obtain compound c-1.
[0133] After obtaining compound C-1, the present invention mixes the compound C-1 with trifluoroacetic acid and performs a hydrolysis reaction (referred to as the third hydrolysis reaction) to obtain a Pyclen ligand having a structure represented by Formula II. In the present invention, the raw material ratio, reaction conditions, and post-treatment method used in the third hydrolysis reaction are preferably the same as those used in the first hydrolysis reaction and are not further described herein.
[0134] In the present invention, when R′ in formula ii is -H, the preparation method of the Pyclen ligand having the structure shown in formula ii comprises the following steps:
[0135] Compound c is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction (referred to as the fourth hydrolysis reaction) to obtain a Pyclen ligand having a structure shown in Formula ii.
[0136] In the present invention, the raw material ratio, reaction conditions and post-treatment method used in the fourth hydrolysis reaction are preferably consistent with those of the first hydrolysis reaction, and will not be repeated here.
[0137] In the present invention, when R′ in formula iii is not -H, the preparation method of the Pyclen ligand having the structure shown in formula iii comprises the following steps:
[0138] Compound d, R′-Br, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound d-1;
[0139] Mixing the compound d-1, lithium hydroxide, methanol and water to perform a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula III;
[0140] The structural formulas of compound d and compound d-1 are shown below:
[0141] The R 1 、R 2 , R′ and R″ are as defined in formula iii.
[0142] In the present invention, when R' in formula iii is not -H, the reaction formula for preparing the Pyclen ligand having the structure shown in formula iii is as follows:
[0143] In the present invention, compound d, R'-Br, potassium carbonate, and acetonitrile are mixed and subjected to a nucleophilic substitution reaction (referred to as the fourth nucleophilic substitution reaction) to obtain compound d-1. In the present invention, the molar ratio of compound d, R'-Br, and potassium carbonate is preferably 1:1.3-1.7:1.8-2.2, more preferably 1:1.5:2. The acetonitrile is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, compound d is preferably dissolved in acetonitrile, followed by the addition of potassium carbonate and R'-Br in sequence to conduct the fourth nucleophilic substitution reaction. In the present invention, the temperature of the fourth nucleophilic substitution reaction is preferably 45-55°C, more preferably 50°C, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the fourth nucleophilic substitution reaction, the resulting product system is preferably filtered to remove insoluble solids, the solvent is evaporated from the filtrate under reduced pressure, and the residue is purified by column chromatography (preferably using a 10:1 volume ratio of dichloromethane to methanol as the eluent) to obtain compound d-1.
[0144] After obtaining compound d-1, the present invention mixes compound d-1, lithium hydroxide, methanol, and water to perform a hydrolysis reaction (referred to as the fifth hydrolysis reaction) to obtain a Pyclen ligand having a structure represented by Formula III. In the present invention, the raw material ratio, reaction conditions, and post-treatment method used in the fifth hydrolysis reaction are preferably the same as those used in the second hydrolysis reaction and are not further described here.
[0145] In the present invention, when R′ in formula iii is -H, the preparation method of the Pyclen ligand having the structure shown in formula iii comprises the following steps:
[0146] Compound d, lithium hydroxide, methanol and water are mixed and subjected to a hydrolysis reaction (recorded as the sixth hydrolysis reaction) to obtain a Pyclen ligand having a structure shown in Formula iii.
[0147] In the present invention, the raw material ratio, reaction conditions and post-treatment method used in the sixth hydrolysis reaction are preferably consistent with those of the second hydrolysis reaction, and will not be repeated here.
[0148] In the present invention, the preparation method of the Pyclen ligand having the structure shown in Formula IV comprises the following steps:
[0149] Compound a, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound a-2;
[0150] Mixing the compound a-2 with trifluoroacetic acid and performing a deprotection reaction to obtain compound a-3;
[0151] The compound a-3, compound a-4, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound a-5;
[0152] The compound a-5, lithium hydroxide, methanol and water are mixed to carry out a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula IV;
[0153] The structural formulas of compound a-2, compound a-3, compound a-4 and compound a-5 are shown below:
[0154] The R 1 、R 2 , R″ and R″′ are as defined in formula iv.
[0155] In the present invention, the reaction formula for preparing the Pyclen ligand having the structure shown in Formula iv is as follows:
[0156] In the present invention, compound a, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to perform a nucleophilic substitution reaction (referred to as the fifth nucleophilic substitution reaction) to obtain compound a-2. In the present invention, the raw material ratio, reaction conditions and post-treatment method used in the fifth nucleophilic substitution reaction are preferably consistent with those of the first nucleophilic substitution reaction and are not further described herein.
[0157] After obtaining compound a-2, the present invention mixes the compound a-2 with trifluoroacetic acid and performs a deprotection reaction to obtain compound a-3. In the present invention, the amount ratio of the compound a-2 to trifluoroacetic acid is preferably 1 mmol: 80 to 120 mL, more preferably 1 mmol: 100 mL. In the present invention, the temperature of the deprotection reaction is preferably 85 to 95°C, more preferably 90°C; the time of the deprotection reaction is based on ensuring that the compound a-2 is completely hydrolyzed, and specifically HPLC can be used to monitor the reaction. After the deprotection reaction, the present invention preferably evaporates the solvent from the obtained product system under reduced pressure, and the residue is purified by column chromatography (the eluent used is preferably dichloromethane: methanol = 10: 1 by volume ratio) to obtain compound a-3.
[0158] After obtaining compound a-3, the present invention mixes the compound a-3, compound a-4, potassium carbonate and acetonitrile to perform a nucleophilic substitution reaction (referred to as the sixth nucleophilic substitution reaction) to obtain compound a-5. In the present invention, the raw material ratio, reaction conditions and post-treatment method used in the sixth nucleophilic substitution reaction are preferably consistent with those of the third nucleophilic substitution reaction and are not further described herein.
[0159] After obtaining compound a-5, the present invention mixes the compound a-5, lithium hydroxide, methanol and water to carry out a hydrolysis reaction (recorded as the seventh hydrolysis reaction) to obtain a Pyclen ligand having a structure shown in formula iv. In the present invention, the molar ratio of the compound a-5 to lithium hydroxide is preferably 1:5.5-6.5, more preferably 1:6; the volume ratio of the methanol to water is preferably 1:0.8-1.2, more preferably 1:1, and the methanol and water are used as solvents in an amount that ensures the smooth progress of the reaction. The present invention preferably dissolves compound a-5 in methanol, and then adds an aqueous solution of lithium hydroxide to carry out the seventh hydrolysis reaction. In the present invention, the temperature of the seventh hydrolysis reaction is preferably 15-35°C, more preferably room temperature; the time is preferably 10-15h, more preferably 12h. After the seventh hydrolysis reaction, the present invention preferably adjusts the pH value of the resulting product system to 6 with dilute hydrochloric acid, separates it using semi-preparative HPLC, combines the separated liquid phases, removes acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water under reduced pressure, and freeze-dries the remaining liquid to obtain a Pyclen ligand having a structure shown in Formula IV.
[0160] In the present invention, the preparation method of the Pyclen ligand having the structure shown in Formula V comprises the following steps:
[0161] Compound c, compound a-4, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound c-2;
[0162] Mixing the compound c-2 with trifluoroacetic acid to carry out a first-stage hydrolysis reaction to obtain a hydrolysis intermediate;
[0163] The hydrolysis intermediate, lithium hydroxide, methanol and water are mixed to carry out a second-stage hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula V;
[0164] The structural formula of the compound c-2 is shown below:
[0165] The R 1 、R 2 , R″ and R″′ are as defined in formula v.
[0166] In the present invention, the reaction formula for preparing the Pyclen ligand having the structure shown in formula v is as follows:
[0167] In the present invention, compound c, compound a-4, potassium carbonate and acetonitrile are mixed to perform a nucleophilic substitution reaction (referred to as the seventh nucleophilic substitution reaction) to obtain compound c-2. In the present invention, the raw material ratio, reaction conditions and post-treatment method used in the seventh nucleophilic substitution reaction are preferably consistent with those of the third nucleophilic substitution reaction and are not further described herein.
[0168] After obtaining compound C-2, the present invention mixes the compound C-2 with trifluoroacetic acid and performs a first-stage hydrolysis reaction to obtain a hydrolysis intermediate. In the present invention, the raw material ratio and reaction conditions used in the first-stage hydrolysis reaction are preferably the same as those in the first hydrolysis reaction and are not described in detail herein. After the first-stage hydrolysis reaction, the present invention preferably removes the solvent from the obtained product system under reduced pressure, and the obtained residue is directly subjected to the next reaction.
[0169] After obtaining the hydrolysis intermediate, the present invention mixes the hydrolysis intermediate, lithium hydroxide, methanol and water to carry out a second-stage hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula V. In the present invention, based on the amount of the compound c-2 used, the molar ratio of the compound c-2 to lithium hydroxide is preferably 1:1.8 to 2.2, more preferably 1:2; the volume ratio of the methanol to water is preferably 1:0.8 to 1.2, more preferably 1:1. The methanol and water are used as solvents in amounts that ensure the smooth progress of the reaction. In the present invention, the reaction conditions and post-treatment methods of the second-stage hydrolysis reaction are preferably consistent with those of the second hydrolysis reaction and are not repeated here.
[0170] In the present invention, the preparation method of the Pyclen ligand having the structure shown in Formula VI comprises the following steps:
[0171] Compound d, compound a-4, potassium carbonate and acetonitrile are mixed to undergo a nucleophilic substitution reaction to obtain compound d-2;
[0172] Mixing the compound d-2, lithium hydroxide, methanol and water to carry out a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in Formula VI;
[0173] The structural formula of the compound d-2 is shown below:
[0174] The R 1 、R 2 , R″ and R″′ are as defined in formula vi.
[0175] In the present invention, the reaction formula for preparing the Pyclen ligand having the structure shown in formula vi is as follows:
[0176] In the present invention, compound d, compound a-4, potassium carbonate and acetonitrile are mixed to perform a nucleophilic substitution reaction (referred to as the eighth nucleophilic substitution reaction) to obtain compound d-2. In the present invention, the raw material ratio, reaction conditions and post-treatment method used in the eighth nucleophilic substitution reaction are preferably consistent with those of the third nucleophilic substitution reaction and are not further described here.
[0177] After obtaining compound d-2, the present invention mixes compound d-2, lithium hydroxide, methanol, and water to perform a hydrolysis reaction (referred to as the eighth hydrolysis reaction) to obtain a Pyclen ligand having a structure represented by formula VI. In the present invention, the raw material ratio, reaction conditions, and post-treatment method used in the eighth hydrolysis reaction are preferably the same as those of the seventh hydrolysis reaction and are not further described here.
[0178] The following describes the preparation method of the reactants required for preparing the Pyclen ligand in the present invention.
[0179] In the present invention, the reaction formula for preparing compound a is as follows:
[0180] In the present invention, the preparation method of compound a preferably comprises the following steps:
[0181] Compound 3-a, compound 2-a, sodium carbonate and N,N-dimethylformamide are mixed and subjected to a ring-closure reaction to obtain compound 1-a;
[0182] The compound 1-a, cesium carbonate, isopropyl mercaptan and acetonitrile are mixed and subjected to a deprotection reaction to obtain compound a.
[0183] In the present invention, compound 3-a, compound 2-a, sodium carbonate, and N,N-dimethylformamide are mixed and subjected to a ring-closure reaction to obtain compound 1-a. In the present invention, the molar ratio of compound 3-a, compound 2-a, and sodium carbonate is preferably 1:0.9-1.3:3.5-4.5, more preferably 1:1.1:4. The N,N-dimethylformamide is used as a solvent in an amount sufficient to ensure the smooth progress of the reaction. In the present invention, the ring-closure reaction temperature is preferably 15-35°C, more preferably room temperature, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the ring-closure reaction, the present invention preferably mixes the resulting product system with water, filters the precipitate, and sequentially washes and dries the resulting filter cake to obtain compound 1-a.
[0184] After obtaining compound 1-a, the present invention mixes the compound 1-a, cesium carbonate, isopropyl mercaptan, and acetonitrile to perform a deprotection reaction to obtain compound a. In the present invention, the molar ratio of compound 1-a, cesium carbonate, and isopropyl mercaptan is preferably 1:5.5-6.5:5.5-6.5, more preferably 1:6:6; the acetonitrile is used as a solvent in an amount that ensures the reaction proceeds smoothly. In the present invention, the temperature of the deprotection reaction is preferably 15-35°C, more preferably room temperature; the time is preferably 10-15 hours, more preferably 12 hours. After the deprotection reaction, the present invention preferably filters the resulting product system to remove solid insoluble matter, evaporates the filtrate under reduced pressure to remove the solvent, and purifies the residue by column chromatography (the eluent used is preferably dichloromethane:methanol = 10:1 by volume) to obtain compound a.
[0185] The present invention preferably uses the compound 3-a wherein R 1 With R 2 Different preparation methods are selected for specific types, which are described in detail below.
[0186] In the present invention, when R 1 With R 2 At different times, the reaction formula for preparing the compound 3-a is as follows:
[0187] In the present invention, when R 1 With R 2 When different, the preparation method of compound 3-a preferably comprises the following steps:
[0188] Compound 7-a, p-nitrobenzenesulfonyl chloride, pyridine and dichloromethane were mixed to undergo a nucleophilic substitution-ring closure reaction to obtain compound 6-a;
[0189] The compound 6-a, p-methoxybenzylamine and acetonitrile are mixed and subjected to a nucleophilic addition reaction to obtain a product system containing compound 5-a;
[0190] The product system containing compound 5-a is mixed with compound 4-a, and a nucleophilic addition reaction is carried out to obtain compound 3-a.
[0191] The present invention mixes compound 7-a, p-nitrobenzenesulfonyl chloride, pyridine, and dichloromethane to perform a nucleophilic substitution-ring closure reaction to obtain compound 6-a. In the present invention, the molar ratio of compound 7-a to p-nitrobenzenesulfonyl chloride is preferably 1:2.8-3.2, more preferably 1:3; the amount ratio of compound 7-a to pyridine is preferably 300 mmol:80-100 mL, more preferably 300 mmol:90 mL; the amount of dichloromethane used as a solvent is sufficient to ensure the smooth progress of the reaction. The present invention preferably dissolves compound 7-a in dichloromethane, then adds pyridine, cools the reaction system to 0-5°C in an ice bath, adds p-nitrobenzenesulfonyl chloride, and performs a nucleophilic substitution-ring closure reaction. In the present invention, the nucleophilic substitution-ring-closure reaction preferably includes a first-stage reaction and a second-stage reaction in sequence; the temperature of the first-stage reaction is preferably 0-5°C, the time is preferably 1.5-2.5h, more preferably 2h; the temperature of the second-stage reaction is preferably 15-35°C, and the time is preferably based on the complete reaction. Specifically, TLC can be used to monitor the reaction. After the nucleophilic substitution-ring-closure reaction, the present invention preferably extracts the resulting product system with dichloromethane, washes the organic phase with 2 mol / L hydrochloric acid to remove pyridine, and then sequentially washes with 2 mol / L potassium hydroxide solution, water, and saturated brine, dries over anhydrous sodium sulfate, filters, and removes the solvent from the filtrate by rotary evaporation. The residue is purified by column chromatography (the eluent used is preferably petroleum ether: ethyl acetate = 5:1 by volume) to obtain compound 6-a.
[0192] After obtaining compound 6-a, the present invention mixes the compound 6-a, p-methoxybenzylamine and acetonitrile to carry out a nucleophilic addition reaction (referred to as the first nucleophilic addition reaction) to obtain a product system containing compound 5-a. In the present invention, the molar ratio of compound 6-a to p-methoxybenzylamine is preferably 1.8 to 2.2: 1, more preferably 2: 1; the acetonitrile is used as a solvent in an amount sufficient to ensure the smooth progress of the reaction. In the present invention, the temperature of the first nucleophilic addition reaction is preferably 70 to 80°C, more preferably 75°C; the time is preferably based on the complete reaction, and HPLC can be used to monitor the reaction. After the first nucleophilic addition reaction, the present invention does not require post-treatment, and the product system containing compound 5-a is directly subjected to the next reaction.
[0193] After obtaining a product system containing compound 5-a, the present invention mixes the product system containing compound 5-a with compound 4-a and conducts a nucleophilic addition reaction (referred to as the second nucleophilic addition reaction) to obtain compound 3-a. In the present invention, based on the amount of compound 6-a used, the molar ratio of compound 6-a to compound 4-a is preferably 1:0.8-1.2, more preferably 1:1. In the present invention, the temperature of the second nucleophilic addition reaction is preferably 70-80°C, more preferably 75°C; the time is preferably based on complete reaction, and the reaction can be monitored by HPLC. After the second nucleophilic addition reaction, the present invention preferably removes the solvent from the obtained product system under reduced pressure, and the residue is purified by column chromatography (the eluent used is preferably petroleum ether:ethyl acetate = 2:1 by volume) to obtain compound 3-a.
[0194] In the present invention, when R 1 With R 2 When the reaction is the same, the reaction formula for preparing the compound 3-a is as follows:
[0195] In the present invention, when R 1 With R 2 When the same, the preparation method of the compound 3-a preferably comprises the following steps:
[0196] Compound 6-a, p-methoxybenzylamine and acetonitrile are mixed and subjected to a nucleophilic addition reaction (referred to as the third nucleophilic addition reaction) to obtain compound 3-a.
[0197] In the present invention, the molar ratio of compound 6-a to p-methoxybenzylamine is preferably 1.8 to 2.2:1, more preferably 2:1; acetonitrile is used as a solvent in an amount sufficient to ensure the smooth progress of the reaction. In the present invention, the conditions and post-treatment method of the third nucleophilic addition reaction are preferably the same as those of the second nucleophilic addition reaction and are not further described here.
[0198] In the present invention, the reaction formula for preparing compound c is as follows:
[0199] In the present invention, the preparation method of compound c preferably comprises the following steps:
[0200] Compound 3-c, compound 2-a, potassium carbonate and N,N-dimethylformamide are mixed and subjected to a ring-closure reaction to obtain compound 2-c;
[0201] The compound 2-c, cesium carbonate, isopropyl mercaptan and acetonitrile are mixed and subjected to a deprotection reaction to obtain compound 1-c;
[0202] The compound 1-c, tert-butyl bromoacetate, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound c.
[0203] The present invention mixes compound 3-c, compound 2-a, potassium carbonate, and N,N-dimethylformamide to undergo a ring-closure reaction to obtain compound 2-c. In the present invention, the molar ratio of compound 3-c, compound 2-a, and potassium carbonate is preferably 1:0.9-1.3:3.5-4.5, more preferably 1:1.1:4. The N,N-dimethylformamide is used as a solvent in an amount sufficient to ensure the smooth progress of the reaction. In the present invention, the ring-closure reaction temperature is preferably 15-35°C, more preferably room temperature, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the ring-closure reaction, the present invention preferably mixes the resulting product system with water, precipitates, filters, and sequentially washes and dries the resulting filter cake to obtain compound 2-c.
[0204] After obtaining compound 2-c, the present invention mixes the compound 2-c, cesium carbonate, isopropyl mercaptan, and acetonitrile to perform a deprotection reaction to obtain compound 1-c. In the present invention, the molar ratio of compound 2-c, cesium carbonate, and isopropyl mercaptan is preferably 1:5.5-6.5:5.5-6.5, more preferably 1:6:6; the acetonitrile is used as a solvent in an amount that ensures the reaction proceeds smoothly. In the present invention, the temperature of the deprotection reaction is preferably 15-35°C, more preferably room temperature; the time is preferably 10-15 hours, more preferably 12 hours. After the deprotection reaction, the present invention preferably filters the resulting product system to remove solid insoluble matter, evaporates the solvent from the filtrate under reduced pressure, and purifies the residue by column chromatography (the eluent used is preferably dichloromethane:methanol = 10:1 by volume) to obtain compound 1-c.
[0205] After obtaining compound 1-c, the present invention mixes the compound 1-c, tert-butyl bromoacetate, potassium carbonate and acetonitrile to perform a nucleophilic substitution reaction to obtain compound c. In the present invention, the molar ratio of compound 1-c, tert-butyl bromoacetate and potassium carbonate is preferably 1:0.8-1.2:1.8-2.2, more preferably 1:1:2; the acetonitrile is used as a solvent in an amount that ensures the smooth progress of the reaction. In the present invention, the temperature of the nucleophilic substitution reaction is preferably 45-55°C, more preferably 50°C; the time is preferably 10-15h, more preferably 12h. After the nucleophilic substitution reaction, the present invention preferably purifies the residue by column chromatography (the eluent used is dichloromethane:methanol = 5:1 by volume) to obtain compound c.
[0206] The present invention preferably uses the compound 3-c wherein R 1 With R 2 Different preparation methods are selected for specific types, which are described in detail below.
[0207] In the present invention, when R 1 With R 2 At different times, the reaction formula for preparing the compound 3-c is as follows:
[0208] In the present invention, when R 1 With R 2 When different, the preparation method of the compound 3-c preferably comprises the following steps:
[0209] Compound 6-a, tert-butyl aminoacetate and acetonitrile are mixed and subjected to a nucleophilic addition reaction to obtain a product system containing compound 4-c;
[0210] The product system containing compound 4-c is mixed with compound 4-a, and a nucleophilic addition reaction is carried out to obtain compound 3-c.
[0211] The present invention mixes compound 6-a, tert-butyl aminoacetate and acetonitrile, and conducts a nucleophilic addition reaction (recorded as the fourth nucleophilic addition reaction) to obtain a product system containing compound 4-c. In the present invention, the molar ratio of compound 6-a to tert-butyl aminoacetate is preferably 1.8 to 2.2: 1, more preferably 2: 1; the acetonitrile is used as a solvent in an amount that ensures the smooth progress of the reaction. In the present invention, the temperature of the fourth nucleophilic addition reaction is preferably 70 to 80°C, more preferably 75°C; the time is preferably based on the complete reaction, and specifically, HPLC can be used to monitor the reaction. After the fourth nucleophilic addition reaction, the present invention does not require post-treatment, and the product system containing compound 4-c is directly subjected to the next reaction.
[0212] After obtaining a product system containing compound 4-c, the present invention mixes the product system containing compound 4-c with compound 4-a and conducts a nucleophilic addition reaction (referred to as the fifth nucleophilic addition reaction) to obtain compound 3-c. In the present invention, based on the amount of compound 6-a used, the molar ratio of compound 6-a to compound 4-a is preferably 1:0.8-1.2, more preferably 1:1. In the present invention, the temperature of the fifth nucleophilic addition reaction is preferably 70-80°C, more preferably 75°C; the time is preferably based on complete reaction, and the reaction can be monitored by HPLC. After the fifth nucleophilic addition reaction, the present invention preferably removes the solvent from the obtained product system under reduced pressure, and the residue is purified by column chromatography (the eluent used is preferably petroleum ether:ethyl acetate = 5:1 by volume) to obtain compound 3-c.
[0213] In the present invention, when R 1 With R 2When the reaction is the same, the reaction formula for preparing the compound 3-c is as follows:
[0214] In the present invention, when R 1 With R 2 When the same, the preparation method of the compound 3-c preferably comprises the following steps:
[0215] Compound 6-a, tert-butyl aminoacetate and acetonitrile are mixed and subjected to a nucleophilic addition reaction (recorded as the sixth nucleophilic addition reaction) to obtain compound 3-c.
[0216] In the present invention, the molar ratio of compound 6-a to tert-butyl aminoacetate is preferably 1.8 to 2.2:1, more preferably 2:1; acetonitrile is used as a solvent in an amount sufficient to ensure the smooth progress of the reaction. In the present invention, the conditions and post-treatment method of the sixth nucleophilic addition reaction are preferably the same as those of the fifth nucleophilic addition reaction and are not further described here.
[0217] In the present invention, the reaction formula for preparing compound d is as follows:
[0218] In the present invention, the preparation method of compound d preferably comprises the following steps:
[0219] Compound 6-a, compound 7-d, N,N-diisopropylethylamine and acetonitrile are mixed and subjected to a nucleophilic addition reaction to obtain compound 6-d;
[0220] The compound 6-d is mixed with a BH3·THF solution and subjected to a reduction reaction to obtain compound 5-d;
[0221] The compound 5-d, p-toluenesulfonyl chloride, triethylamine and dichloromethane are mixed to carry out a nucleophilic substitution reaction to obtain compound 4-d;
[0222] The compound 4-d, compound 2-a, sodium carbonate and N,N-dimethylformamide are mixed to perform a ring-closure reaction to obtain compound 3-d;
[0223] The compound 3-d, glacial acetic acid and hydrobromic acid are mixed to carry out a deprotection reaction to obtain compound 2-d;
[0224] The compound 2-d, potassium carbonate, ethyl bromoacetate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound 1-d;
[0225] The compound 1-d, cesium carbonate, isopropyl mercaptan and acetonitrile are mixed and subjected to a deprotection reaction to obtain compound d.
[0226] In the present invention, compound 6-a, compound 7-d, N,N-diisopropylethylamine, and acetonitrile are mixed and subjected to a nucleophilic addition reaction to obtain compound 6-d. In the present invention, the molar ratio of compound 6-a, compound 7-d, and N,N-diisopropylethylamine is preferably 1:0.8-1.2:1.8-2.2, more preferably 1:1:2. Acetonitrile is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, compound 7-d, N,N-diisopropylethylamine, and acetonitrile are preferably mixed, followed by the addition of compound 6-a to carry out the nucleophilic addition reaction. In the present invention, the temperature of the nucleophilic addition reaction is preferably 65-75°C, more preferably 70°C, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the nucleophilic addition reaction, the solvent is preferably evaporated under reduced pressure from the resulting product system, and the residue is washed with ethyl acetate and dried to obtain compound 6-d.
[0227] After obtaining compound 6-d, the present invention mixes compound 6-d with a BH3·THF solution and performs a reduction reaction to obtain compound 5-d. In the present invention, the BH3·THF solution is specifically a solution of BH3 dissolved in tetrahydrofuran; the concentration of the BH3·THF solution is preferably 2 mol / L; the molar ratio of compound 6-d to BH3·THF is preferably 1:9-11, more preferably 1:10. In the present invention, the reduction reaction is preferably carried out under reflux conditions; the reduction reaction time is based on complete reaction, and the reaction can be monitored using HPLC. After the reduction reaction, the present invention preferably adds methanol to the resulting product system, continues to reflux for 2 hours, and then evaporates the solvent under reduced pressure to obtain compound 5-d.
[0228] After obtaining compound 5-d, the present invention mixes compound 5-d, p-toluenesulfonyl chloride, triethylamine, and dichloromethane to conduct a nucleophilic substitution reaction to obtain compound 4-d. In the present invention, the molar ratio of compound 5-d, p-toluenesulfonyl chloride, and triethylamine is preferably 1:2.8-3.2:2.8-3.2, more preferably 1:3:3. The dichloromethane is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, compound 5-d is preferably dissolved in dichloromethane, followed by the addition of triethylamine. The mixture is cooled to 0°C in an ice bath, and p-toluenesulfonyl chloride is added in portions to conduct the nucleophilic substitution reaction. In the present invention, the nucleophilic substitution reaction preferably comprises a first-stage reaction and a second-stage reaction. The first-stage reaction is preferably conducted at a temperature of 0°C and for a time of 25-35 minutes, more preferably 30 minutes. The second-stage reaction is preferably conducted at a temperature of 15-35°C, more preferably room temperature, and the reaction time is preferably based on sufficient reaction. Specifically, the reaction can be monitored using TLC. After the nucleophilic substitution reaction, the present invention preferably extracts the obtained product system with dichloromethane, combines the organic phases, washes with saturated brine, and dries with anhydrous sodium sulfate, filters, and removes the solvent from the filtrate by rotary evaporation. The residue is purified by column chromatography (the eluent used is preferably petroleum ether: ethyl acetate = 3:1 by volume) to obtain compound 4-d.
[0229] After obtaining compound 4-d, the present invention mixes compound 4-d, compound 2-a, sodium carbonate, and N,N-dimethylformamide to undergo a ring-closure reaction to obtain compound 3-d. In the present invention, the molar ratio of compound 4-d, compound 2-a, and sodium carbonate is preferably 1:0.9-1.3:3.4-4.5, more preferably 1:1.1:4. The N,N-dimethylformamide is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, the ring-closure reaction temperature is preferably 15-35°C, more preferably room temperature, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the ring-closure reaction, the present invention mixes the resulting product system with water to precipitate, which is then filtered. The resulting filter cake is then washed with water and dried to obtain compound 3-d.
[0230] After obtaining compound 3-d, the present invention mixes compound 3-d, glacial acetic acid, and hydrobromic acid to perform a deprotection reaction to obtain compound 2-d. In the present invention, the concentration of the hydrobromic acid is preferably 45-50 wt%, more preferably 48 wt%; the volume ratio of the glacial acetic acid to the hydrobromic acid is preferably 30-40:60-70, more preferably 35:65; and the ratio of the total volume of the glacial acetic acid and hydrobromic acid to the amount of compound 3-d is preferably 45-55 mL:8 mmol, more preferably 50 mL:8 mmol. In the present invention, the temperature of the deprotection reaction is preferably 105-115°C, more preferably 110°C; and the time is preferably 45-50 hours, more preferably 48 hours. After the deprotection reaction, the present invention preferably removes the solvent from the resulting product system under reduced pressure, and the residue is purified by column chromatography (preferably using a 5:1 volume ratio of dichloromethane to methanol as the eluent) to obtain compound 2-d.
[0231] After obtaining compound 2-d, the present invention combines compound 2-d, potassium carbonate, ethyl bromoacetate, and acetonitrile to undergo a nucleophilic substitution reaction to obtain compound 1-d. In the present invention, the molar ratio of compound 2-d, potassium carbonate, and ethyl bromoacetate is preferably 1:9-11:4.5-5.5, more preferably 1:10:5. The acetonitrile is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, compound 2-d is preferably dissolved in acetonitrile, followed by the addition of potassium carbonate and ethyl bromoacetate. In the present invention, the temperature for the nucleophilic substitution reaction is preferably 45-55°C, more preferably 50°C, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the nucleophilic substitution reaction, the present invention preferably filters the resulting product to remove insoluble solids, evaporates the filtrate under reduced pressure to remove the solvent, and purifies the residue by column chromatography (preferably using a 10:1 volume ratio of dichloromethane to methanol as the eluent) to obtain compound 1-d.
[0232] After obtaining compound 1-d, the present invention mixes compound 1-d, cesium carbonate, isopropyl mercaptan, and acetonitrile to perform a deprotection reaction to obtain compound d. In the present invention, the molar ratio of compound 1-d, cesium carbonate, and isopropyl mercaptan is preferably 1:5.5-6.5:5.5-6.5, more preferably 1:6:6. The acetonitrile is used as a solvent in an amount sufficient to ensure smooth reaction. In the present invention, the temperature of the deprotection reaction is preferably 15-35°C, more preferably room temperature, and the reaction time is preferably 10-15 hours, more preferably 12 hours. After the deprotection reaction, the present invention preferably filters the resulting product system to remove solid insoluble matter, evaporates the filtrate under reduced pressure to remove the solvent, and purifies the residue by column chromatography (preferably using a 5:1 volume ratio of dichloromethane to methanol as the eluent) to obtain compound d.
[0233] The present invention provides a Pyclen complex having a structure shown in any one of Formulas I to VI:
[0234] R in the formulas I to VI 1 and R 2 , R' in formula I to III, R" in formula I to VI and R"' in formula IV to VI are as defined in claim 1 or 2, R 1 and R 2 Can be the same or different;
[0235] In the formulas I to III, M1 is Mn(II), Fe(III), Co(II), Cu(II) or Ni(II);
[0236] In the formulas IV to VI, M2 is a lanthanide metal ion.
[0237] In the present invention, the M1 is preferably Mn(II). Mn(II) ion is an endogenous ion and has higher safety than Gd ion within a certain dosage range. Therefore, a contrast agent based on Mn(II) ion can be developed.
[0238] In the present invention, the M2 is preferably Gd(III), Eu(III), Tb(III) or Yb(III).
[0239] In the present invention, the compounds represented by Formulas I to III are hexacoordinated Pyclen complexes, and the compounds represented by Formulas IV to VI are octacoordinated Pyclen complexes. The stability of the complexes is determined by their structure. The pyridine group in the parent ring structure imposes certain limitations on the rigidity of the macrocyclic backbone. Introducing a chiral group, i.e., R, into the parent ring further enhances the rigidity of the ring structure, thereby improving the stability of the Pyclen complexes. Introducing a lipophilic group, R', into the Pyclen complexes represented by Formulas I to III can increase their distribution in the liver and gallbladder as contrast agents, enhancing their hepatobiliary imaging capabilities. Introducing a group R" onto the pyridine of the Pyclen ring in the Pyclen complexes represented by Formulas I to VI, or introducing a group R"' onto the pyridine sidearm of the Pyclen complexes represented by Formulas IV to VI, can increase the diversity of their modifications and change the solubility, metabolic properties, and other properties of the complexes.
[0240] In the present invention, the Pyclen complex is preferably any one of the following compounds:
[0241] The present invention provides a method for preparing the Pyclen complex described in the above technical solution, comprising the following steps:
[0242] A pyclen ligand, a soluble metal salt and water are mixed to carry out a complexation reaction to obtain a pyclen complex having a structure shown in any one of formulas I to VI; the pyclen ligand is the pyclen ligand described in the above technical solution; and the metal ion in the soluble metal salt is M1 or M2.
[0243] In the present invention, the soluble metal salt is preferably a hydrochloride, specifically FeCl3, NiCl2, CuCl2·2H2O, CoCl2·6H2O, MnCl2·4H2O, GdCl3·6H2O, EuCl3·6H2O, YbCl3·6H2O or TbCl3·6H2O.
[0244] In the present invention, the molar ratio of the Pyclen ligand to the metal in the soluble metal salt is preferably 1:1. The present invention preferably controls the molar ratio of the raw materials within the above range, which is beneficial for improving the yield of the complex. In the present invention, the complexation reaction is preferably carried out at a system pH of 6.3 to 6.7 (more preferably 6.5), and the reagent used to adjust the pH is preferably lithium hydroxide solution. When the Pyclen ligand is a compound represented by Formulas i to iii, the complexation reaction is preferably carried out at room temperature for 8 to 24 hours, more preferably 10 to 15 hours. When the Pyclen ligand is a compound represented by Formulas iv to vi, the complexation reaction temperature is preferably 90 to 110°C, more preferably 95 to 105°C, and the complexation reaction time is preferably 8 to 24 hours, more preferably 10 to 15 hours. In the present invention, the Pyclen ligand is preferably dissolved in water, and then the soluble metal salt is added. The complexation reaction is carried out using lithium hydroxide solution to adjust the system pH to within the above range. Controlling the complexation reaction conditions within the above range is beneficial for improving the yield of the complex. When the Pyclen ligand is a compound represented by formula i to iii, after the complex reaction, the present invention preferably centrifuges the resulting product system, filters the supernatant through a 0.22 μm membrane, and lyophilizes to obtain a Pyclen complex. When the Pyclen ligand is a compound represented by formula iv to vi, the present invention preferably adjusts the pH value of the resulting product system to 9.3 to 9.7 (preferably 9.5) with a lithium hydroxide solution, centrifuges, filters the supernatant through a 0.22 μm membrane, and readjusts the filtrate to a pH of 6.3 to 6.7 (further preferably 6.5) with hydrochloric acid, and lyophilizes to obtain a Pyclen complex.
[0245] The present invention provides a pharmaceutical composition comprising the Pyclen complex described in the technical solution of the claims and a pharmaceutically acceptable carrier. The present invention does not particularly limit the specific type of the pharmaceutically acceptable carrier; any pharmaceutically acceptable carrier well known to those skilled in the art can be used. The present invention does not particularly limit the content of the Pyclen complex in the pharmaceutical composition.
[0246] The present invention provides the use of the Pyclen complex described in the above technical solution or the pharmaceutical composition described in the above technical solution in the preparation of a magnetic resonance imaging contrast agent. In the present invention, when the Pyclen complex is a Pyclen complex represented by Formulas I to III, or the pharmaceutical composition contains a Pyclen complex represented by Formulas I to III, the magnetic resonance imaging contrast agent is preferably a hepatobiliary-targeted magnetic resonance imaging contrast agent.
[0247] The present invention provides a magnetic resonance imaging contrast agent, comprising the Pyclen complex or the pharmaceutical composition described in the above technical solution. The present invention does not particularly limit the specific preparation method and use method of the magnetic resonance imaging contrast agent, and methods well known to those skilled in the art can be used.
[0248] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions of the present invention. Obviously, the embodiments described are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.
[0249] Example 1
[0250] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula I, wherein R 1 and R 2 All are -CH2CH3, R' is -H, R" is -H, and are recorded as complex MnL1; the reaction formula is as follows:
[0251] (1) Add (R)-2-amino-1-butanol (26.74 g, 300 mmol, 1.0 equiv.) and dichloromethane (180 mL) to a three-necked flask equipped with a mechanical stirrer. After stirring until the solid is completely dissolved, add pyridine (90 mL). Cool the reaction system to 0-5°C in an ice bath. Slowly add p-nitrobenzenesulfonyl chloride (NsCl, 199.46 g, 900 mmol, 3.0 equiv.). Continue to react in an ice bath for 2.0 h. Remove the ice bath. , stirred at room temperature (25°C) until the reaction was complete as detected by TLC; the resulting product system was extracted three times with dichloromethane, the organic phases were combined, washed with 2 mol / L hydrochloric acid to remove pyridine, and then washed with 2 mol / L potassium hydroxide solution, water and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated to remove the solvent. The residue was purified by column chromatography (the eluent used was petroleum ether: ethyl acetate = 5:1 by volume) to obtain a light yellow oily substance which was compound 1.
[0252] 1 H NMR (400MHz, CDCl3) δ8.39(d,J=8.9Hz,2H),8.24-8.08(m,2H),2.86(tt,J=7.2,4.8Hz,1H),2.74(d,J=7.0Hz,1H ),2.18(d,J=4.7Hz,1H),1.68(ddd,J=14.3,7.2,5.0Hz,1H),1.40(dp,J=14.7,7.4Hz,1H),0.87(t,J=7.4Hz,3H); 13 C NMR (101MHz, CDCl3) δ150.71,144.26,129.40,124.37,77.48,77.16,76.84,42.72,34.53,24.56,10.98.
[0253] (2) Compound 1 (10.25 g, 40 mmol, 2.0 equiv.) and acetonitrile (100 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred to dissolve completely. Then, p-methoxybenzylamine (2.74 g, 20 mmol, 1.0 equiv.) was added. The reaction solution was heated to 75°C and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 2:1 by volume). The light yellow solid obtained was compound 2.
[0254] 1 H NMR (400MHz, CDCl3) δ8.33(d,J=8.9Hz,4H),8.12(d,J=8.9Hz,4H),7.07(d, J=8.5Hz,2H),6.80(d,J=8.6Hz,2H),5.51(s,2H),3.86-3.72(m,4H),3.60( td,J=10.0,5.8Hz,2H),3.11(d,J=13.1Hz,1H),2.53(dd,J=13.3,10.2Hz,2 H),2.36(dd,J=13.4,4.0Hz,2H),1.49-1.32(m,4H),0.66(t,J=7.4Hz,6H); 13 C NMR (101MHz, CDCl3) δ159.12,149.98,147.58,130.53,129.25,128.19,124.43,113.96,77.48,77.16,76.84,57.83,57.38,55.40,53.36, 26.96,9.78.
[0255] (3) Compound 2 (6.49 g, 10 mmol, 1.0 equiv.), 2,6-dibromomethylpyridine (2.91 g, 11 mmol, 1.1 equiv.), sodium carbonate (4.24 g, 40 mmol, 4.0 equiv.) and N,N-dimethylformamide (DMF, 120 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was added to a large amount of water, and a precipitate was precipitated. The precipitate was filtered, and the filter cake was washed with water and dried in sequence to obtain a light yellow solid, compound 3.
[0256] (4) Compound 3 (6.02 g, 10 mmol, 1.0 equiv.) and acetonitrile (100 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the entire compound 3. Cesium carbonate (20.40 g, 48 mmol, 6.0 equiv.) and isopropyl mercaptan (3.66 g, 48 mmol, 6.0 equiv.) were then added and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain compound 4.
[0257] 1 H NMR (400MHz, CDCl3) δ7.48(t,J=7.6Hz,1H),7.22(d,J=8.4Hz,2H),6.94(d, J=7.6Hz,2H),6.82(d,J=8.4Hz,2H),4.19-3.78(m,9H),3.74(s,4H),2.98( d,J=13.3Hz,1H),2.68(s,2H),2.20(t,J=11.7Hz,2H),1.87(d,J=11.0Hz,2 H),1.60-1.40(m,2H),1.13(td,J=14.4,7.3Hz,2H),0.86(t,J=7.3Hz,7H); 13 C NMR (101MHz, CDCl3) δ159.70,158.66,136.63,130.78,130.27,119.89,113 .85,77.48,77.16,76.84,59.04,58.06,55.19,53.79,48.76,24.55,11.28.
[0258] (5) Compound 4 (1.91 g, 5 mmol, 1.0 equiv.) and acetonitrile (20 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 4 completely. Potassium carbonate (6.90 g, 50 mmol, 10.0 equiv.) and tert-butyl bromoacetate (4.88 g, 25 mmol, 5.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the filtrate was evaporated under reduced pressure to remove the solvent, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain compound 5.
[0259] (6) Compound 5 (611 mg, 1 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (10 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the resulting product system was evaporated under reduced pressure, and the residue was dissolved in 15 mL of water and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain compound 6 as a white solid powder.
[0260] 1 H NMR(400MHz,D2O)δ8.33(t,J=7.9Hz,1H),7.74(d,J=7.9Hz,2H),4.41(d,J=57.2Hz,4H),4.18-3.37(m, 5H),3.26(s,1H),2.99(s,3H),2.72(s,1H),2.30(s,1H),1.97-1.62(m,2H),1.38(s,2H),0.86(s,7H); 13 C NMR (101MHz, D2O) δ175.54,153.57,152.50,146.60,124.86,123.85,63.52,59.34,55.80,53.93,50.33,48.53,45.92,21.19,19.45.
[0261] (7) Compound 6 (189 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 6. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL1.
[0262] Example 2
[0263] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula I, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex MnL2; the reaction formula is as follows:
[0264] (1) Compound 4 (1.91 g, 5 mmol, 1.0 equiv.) and acetonitrile were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 4 completely. Potassium carbonate (6.90 g, 50 mmol, 10.0 equiv.) and ethyl bromoacetate (4.18 g, 25 mmol, 5.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain a light yellow semisolid compound 7.
[0265] (2) Compound 7 (1.66 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and then methanol (15 mL) was added to completely dissolve compound 7 to obtain a methanol solution of compound 7; lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 7, stirred at room temperature for 12 h, and monitored by HPLC until the reaction was complete; the resulting product system was adjusted to pH 6 with dilute hydrochloric acid (concentration of 1.0 mol / L), and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 8.
[0266] 1H NMR(400MHz,D2O)δ8.22-8.07(m,1H),7.57(dd,J=12.3,7.9Hz,2H),7.42(d,J=5.2Hz,2H),6.96(d,J=5.7Hz,2H),4.6 7(d,J=17.6Hz,1H),4.54-4.28(m,4H),4.04(dd,J=45.0,17.4Hz,2H),3.76(s,3H),3.66(d,J=12.5Hz,2H),3.30(t,J= 17.5Hz,1H),3.21-3.07(m,1H),2.97(t,J=11.8Hz,2H),2.83(dd,J=30.3,15.5Hz,3H),1.96-1.81(m,1H),1.76(dd,J =11.5,7.1Hz,1H),1.56(dt,J=13.9,7.1Hz,1H),1.13(d,J=30.9Hz,1H),1.02(t,J=7.1Hz,3H),0.71(t,J=7.2Hz,3H); 13 C NMR(101MHz,D2O)δ173.41,171.47,159.62,152.77,149.63,143.62,132.56,124.28,124.11,122.79,11 4.70,63.73,59.91,58.31,57.50,56.80,55.34,53.55,52.41,52.07,48.37,21.36,18.46,10.23,9.77.
[0267] (3) Compound 8 (249 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 8. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL2.
[0268] Example 3
[0269] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula I, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as the complex MnL3; the reaction formula is as follows:
[0270] (1) Compound 1 (10.25 g, 40 mmol, 2.0 equiv.) and acetonitrile (100 mL) were added sequentially to a three-necked flask equipped with a stirrer. The mixture was stirred to dissolve the entire compound 1. 4-Phenylbenzylamine (3.67 g, 20 mmol, 1.0 equiv.) was then added. The reaction solution was heated to 75°C and monitored by HPLC until the reaction was complete. The solvent was removed from the resulting product system under reduced pressure, and the residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 5:1 by volume). The resulting light yellow solid was compound 9.
[0271] 1 H NMR (400MHz, CDCl3) δ8.32 (dd, J=8.8, 2.0Hz, 4H), 8.16-8.09 (m, 4H), 7.58 (d, J=7.7Hz, 2H),7.53(d,J=7.4Hz,2H),7.45(t,J=7.2Hz,2H),7.36(t,J=7.3Hz,1H),7.27(d,J=6.2 Hz,2H),5.56(s,2H),3.91(d,J=11.6Hz,1H),3.64(s,2H),3.24(d,J=12.1Hz,1H),2.59 (s,2H),2.44(d,J=10.6Hz,2H),1.65(s,1H),1.49-1.36(m,4H),0.67(t,J=7.2Hz,6H); 13 C NMR (101MHz, CDCl3) δ149.97,147.51,140.50,129.85,128.99,128.19,127.61,127.26,127.03,124.43,58.22,57.61,53.39,26.89,9.80.
[0272] (2) Compound 9 (6.96 g, 10 mmol, 1.0 equiv.), 2,6-dibromomethylpyridine (2.91 g, 11 mmol, 1.1 equiv.), sodium carbonate (4.24 g, 40 mmol, 4.0 equiv.) and DMF (120 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred at room temperature for 12 h. The reaction was monitored by HPLC until complete. The resulting product system was added to a large amount of water, and a precipitate was precipitated. The precipitate was filtered, and the filter cake was washed with water and dried in sequence to obtain a light yellow solid, compound 10.
[0273] (3) Compound 10 (6.39 g, 8 mmol, 1.0 equiv.) and acetonitrile (100 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the entire compound 10. Cesium carbonate (20.40 g, 48 mmol, 6.0 equiv.) and isopropyl mercaptan (3.66 g, 48 mmol, 6.0 equiv.) were then added and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove the solid insoluble matter, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain compound 11.
[0274] 1 H NMR (400MHz, CDCl3) δ7.69-7.57(m,5H),7.51-7.41(m,4H),7.36(t,J=7.3Hz,1H),7.10(d,J=7.6Hz,2H),4.21(d,J=13.5Hz,1H),4.09(s,4H),3 .33(d,J=13.6Hz,1H),2.93(s,3H),2.44(t,J=12.0Hz,2H),2.17(d,J=1 1.8Hz,2H),1.76-1.58(m,2H),1.39-1.22(m,3H),0.97(t,J=7.1Hz,6H); 13 C NMR (101MHz, CDCl3) δ157.33,141.00,140.41,137.61,136.71,129.94,128.8 2,127.44,127.28,127.23,120.49,58.62,58.28,54.10,47.84,24.14,11.15.
[0275] (4) Compound 11 (2.14 g, 5 mmol, 1.0 equiv.) and acetonitrile were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 11 completely. Potassium carbonate (6.90 g, 50 mmol, 10.0 equiv.) and ethyl bromoacetate (4.18 g, 25 mmol, 5.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the filtrate was evaporated under reduced pressure to remove the solvent, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain a light yellow semisolid compound 12.
[0276] (5) Compound 12 (1.80 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and then methanol (15 mL) was added to completely dissolve compound 12 to obtain a methanol solution of compound 12; lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 12, stirred at room temperature for 12 h, and monitored by HPLC until the reaction was complete; the resulting product system was adjusted to pH 6 with dilute hydrochloric acid, and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 13.
[0277] 1 H NMR(400MHz,D2O)δ8.10(t,J=7.8Hz,1H),7.52(t,J=9.4Hz,6H),7.45(d,J=7.8Hz,2H),7.37(t,J=7.4Hz ,2H),7.28(t,J=7.2Hz,1H),4.66(d,J=17.6Hz,1H),4.54-4.32(m,3H),4.24(d,J=12.6Hz,1H),4.04(s,2 H),3.73-3.44(m,2H),3.31(d,J=17.0Hz,1H),3.11-2.86(m,3H),2.73(dd,J=31.7,14.7Hz,3H),1.96-1. 82(m,1H),1.70(dd,J=10.9,7.7Hz,1H),1.60-1.46(m,1H),0.98(t,J=6.6Hz,4H),0.68(t,J=7.0Hz,3H); 13 C NMR(101MHz,D2O)δ172.13,170.45,151.87,149.48,142.99,140.82,139.40,131.90,131.30,129.03,127.87,127.36,126.74,123.86, 122.71,64.30,59.51,58.51,58.02,56.43,53.84,52.75,48.26,20.99,18.54,10.37,9.83.
[0278] (6) Compound 13 (272 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 13. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL3.
[0279] Example 4
[0280] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula II, wherein R 1 and R 2 All are -CH2CH3, R' is -H, R" is -H, and the complex is recorded as MnL4; the reaction formula is as follows:
[0281] (1) Compound 1 (10.25 g, 40 mmol, 2.0 equiv.) and acetonitrile (100 mL) were added sequentially to a three-necked flask equipped with a stirrer. The mixture was stirred to dissolve the entire compound 1. Then, tert-butyl aminoacetate (2.62 g, 20 mmol, 1.0 equiv.) was added. The reaction solution was heated to 75°C and monitored by HPLC until the reaction was complete. The solvent was removed from the resulting product system under reduced pressure, and the residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 5:1 by volume). The obtained light yellow solid was compound 14.
[0282] 1 H NMR (400MHz, CDCl3) δ8.34(d,J=8.8Hz,4H),8.14(d,J=8.8Hz,4H),6.09(d,J=5.7Hz,2H),3.47(dt,J=9.7,4.7Hz,2H),3 .16(q,J=17.6Hz,2H),2.77(dd,J=13.6,4.1Hz,2H),2.53(dd,J=13.6,9.9Hz,2H),1.42(s,13H),0.69(t,J=7.4Hz,6H); 13 C NMR (101MHz, CDCl3) δ170.96,149.95,147.47,128.30,124.35,82.22,57.77,55.51,53.63,28.19,26.56,9.74.
[0283] (2) Compound 14 (6.44 g, 10 mmol, 1.0 equiv.), 2,6-dibromomethylpyridine (2.91 g, 11 mmol, 1.1 equiv.), sodium carbonate (4.24 g, 40 mmol, 4.0 equiv.) and DMF (120 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred at room temperature for 12 h. The reaction was monitored by HPLC until complete. The resulting product system was added to a large amount of water, and a precipitate was precipitated. The precipitate was filtered, and the filter cake was washed with water and dried sequentially to obtain a light yellow solid, compound 15.
[0284] (3) Compound 15 (5.39 g, 8 mmol, 1.0 equiv.) and acetonitrile (100 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the entire compound 15. Cesium carbonate (20.40 g, 48 mmol, 6.0 equiv.) and isopropyl mercaptan (3.66 g, 48 mmol, 6.0 equiv.) were then added and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove the solid insoluble matter, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain compound 16.
[0285] 1 H NMR (400MHz, CDCl3) δ7.49(t,J=7.6Hz,1H),6.95(d,J=7.6Hz,2H),3.89(dd,J=37.5,16.3Hz,4H),3.34(s,2H),2.54(s,2H),2.42(d, J=11.9Hz,2H),2.10(t,J=11.8Hz,2H),1.67-1.48(m,3H),1.43(s,10H),1.20(dt,J=14.2,7.3Hz,2H),0.87(dd,J=15.0,7.5Hz,7H); 13 C NMR (101MHz, CDCl3) δ170.79,160.02,136.63,120.03,81.14,77.38,58.87,56.82,54.19,49.06,28.30,24.63,11.36.
[0286] (4) Compound 16 (1.88 g, 5 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 16 completely. Potassium carbonate (1.38 g, 10 mmol, 2.0 equiv.) and tert-butyl bromoacetate (0.98 g, 5 mmol, 1.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain a light yellow semisolid compound 17.
[0287] (5) Compound 17 (491 mg, 1 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (10 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was dissolved in 15 mL of water and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain compound 18 as a white solid powder.
[0288] 1 H NMR(400MHz,D2O)δ7.89(t,J=7.8Hz,1H),7.39(dd,J=16.7,7.8Hz,2H),4.71 -3.82(m,6H),3.78-3.55(m,2H),3.42(t,J=16.2Hz,1H),3.28(d,J=10.5Hz, 1H),3.10-2.48(m,4H),1.95(dd,J=12.4,6.1Hz,1H),1.83(s,1H),1.55(d,J =5.6Hz,1H),1.49-1.32(m,1H),1.01(t,J=7.3Hz,3H),0.78(t,J=7.2Hz,3H); 13 C NMR(101MHz,D2O)δ174.55,168.73,149.42,148.96,140.16,122.92,121.52,66. 11,57.85,56.82,54.88,54.67,53.54,52.41,45.32,20.71,19.04,10.08,8.93.
[0289] (6) Compound 18 (189 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and then deionized water (5 mL) was added to completely dissolve compound 18. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL4.
[0290] Example 5
[0291] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula II, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex MnL5; the reaction formula is as follows:
[0292] (1) Compound 17 (1.96 g, 4 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 17 completely. Potassium carbonate (11.04 g, 8 mmol, 2.0 equiv.) and 4-phenylbenzyl bromide (1.48 g, 6 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain a light yellow semisolid compound 19.
[0293] (2) Compound 19 (657 mg, 1 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (10 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was dissolved in 15 mL of water and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was Compound 20.
[0294] 1H NMR(400MHz,D2O)δ7.62(t,J=7.8Hz,1H),7.53-7.40(m,8H),7.37(dd,J=8.3,5.8Hz,1H),7.20(d,J=7.9Hz,1H),6.99(d,J=7.7H z,1H),4.82(d,J=2.3Hz,2H),4.58(dd,J=18.6,14.4Hz,2H),4.47(dd,J=14.3,10.5Hz,2H),4.26(d,J=16.9Hz,1H),4.06(d,J=1 6.9Hz,1H),3.64(t,J=10.0Hz,1H),3.58-3.47(m,1H),3.28(s,2H),3.10(dd,J=15.9,3.2Hz,1H),3.05-2.83(m,3H),2.09(dtd, J=10.7,7.5,3.4Hz,1H),1.98-1.82(m,1H),1.72-1.56(m,1H),1.49-1.32(m,1H),1.11(t,J=7.4Hz,3H),0.81(t,J=7.4Hz,3H); 13 C NMR(101MHz,D2O)δ173.54,168.70,149.43,148.46,142.05,140.04,139.09,131.09,129.04,128.11,127.71,127.55 ,126.77,121.78,121.37,64.17,62.43,60.08,55.72,55.52,54.99,53.40,51.83,49.29,19.16,18.32,10.22,9.57.
[0295] (3) Compound 20 (272 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 20. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL5.
[0296] Example 6
[0297] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in formula III, wherein R 1and R 2 All are -CH2CH3, R' is -H, R" is -H, and the complex is recorded as MnL6; the reaction formula is as follows:
[0298] (1) Add (S)-2-amino-1-butanol (26.74 g, 300 mmol, 1.0 equiv.) and dichloromethane (180 mL) to a three-necked flask equipped with a mechanical stirrer. After stirring until the solid is completely dissolved, add pyridine (90 mL). Cool the reaction system to 0-5°C in an ice bath. Slowly add p-nitrobenzenesulfonyl chloride (199.46 g, 900 mmol, 3.0 equiv.). Continue to react in an ice bath for 2.0 h. Remove the ice bath. , stirred at room temperature until the reaction was complete as detected by TLC; the resulting product system was extracted three times with dichloromethane, the organic phases were combined, washed with 2 mol / L hydrochloric acid to remove pyridine, and then washed with 2 mol / L potassium hydroxide solution, water and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated to remove the solvent. The residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 5:1 by volume) to obtain a light yellow oil, which was compound 21.
[0299] 1 H NMR (400MHz, CDCl3) δ8.39 (dd, J=9.0, 2.0Hz, 2H), 8.16 (dd, J=9.0, 2.1Hz, 2H), 2.86 (dq, J=7.2, 4.8Hz, 1H), 2.74 (d,J=7.0Hz,1H),2.18(d,J=4.7Hz,1H),1.80-1.51(m,1H),1.40(dp,J=14.7,7.4Hz,1H),0.87(t,J=7.4Hz,3H); 13 C NMR (101MHz, CDCl3) δ150.70,144.24,129.39,124.37,77.48,77.16,76.84,42.71,34.53,24.55,10.97.
[0300] (2) In a three-necked flask equipped with a stirrer, (S)-2-aminobutanamide hydrochloride (6.64 g, 48 mmol, 1.0 equiv.), acetonitrile (100 mL) and N,N-diisopropylethylamine (DIPEA, 10.32 g, 80 mmol, 2.0 equiv.) were added and stirred until all the solids were dissolved. Stirring was continued for 0.5 h, and then compound 21 (10.24 g, 40 mmol, 1.0 equiv.) was added. The temperature was raised to 70°C and stirred for 12 h. The reaction was monitored by HPLC until completion. The solvent of the obtained product system was evaporated under reduced pressure, and a small amount of ethyl acetate was added to the residue for washing. The light yellow solid obtained after drying was compound 22.
[0301] 1 H NMR (400MHz, MeOD) δ8.44(d,J=8.9Hz,2H),8.17(d,J=8.9Hz,2H),3.95(dd,J=6.8,5.5Hz,1H),3.59-3.40(m,1H),3.23-2.8 0(m,2H),2.14-1.82(m,2H),1.61-1.42(m,1H),1.30(qt,J=14.8,7.4Hz,1H),1.07(t,J=7.5Hz,3H),0.55(t,J=7.4Hz,3H); 13 C NMR(101MHz,MeOD)δ170.90,151.72,147.42,129.73,125.57,63.29,54.26,52. 09,49.64,49.43,49.21,49.00,48.79,48.57,48.36,26.20,24.53,10.20,9.17.
[0302] (3) Compound 22 (10.74 g, 30 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by a 2 mol / L BH3·THF solution (150 mL, 300 mmol, 10.0 equiv.). The mixture was heated to reflux and monitored by HPLC until the reaction was complete. Methanol was added to the resulting product system, and reflux was continued for 2 h. The solvent was then evaporated under reduced pressure to obtain compound 23 as a yellow oil, which did not require further purification and could be used directly in the next step.
[0303] 1H NMR(400MHz,MeOD)δ8.39(d,J=8.8Hz,2H),8.18-8.07(m,2H),3.63-3.46(m,2H),3.46-3.34(m,2H),3.29-3.21(m,2H),3.20-3.0 8(m,1H),1.87(ddt,J=22.3,14.9,5.1Hz,2H),1.49-1.38(m,1H),1.31-1.22(m,1H),1.07(t,J=7.4Hz,3H),0.48(t,J=7.4Hz,3H); 13 C NMR(101MHz,MeOD)δ151.68,147.40,129.80,125.52,59.25,54.05,51.04,49.6 4,49.43,49.21,49.00,48.79,48.57,48.36,39.85,26.26,22.32,10.20,9.46.
[0304] (4) Compound 23 (10.32 g, 30 mmol, 1.0 equiv.) and dichloromethane (200 mL) were added sequentially to a three-necked flask equipped with a mechanical stirrer. The mixture was stirred to dissolve the entire compound 23. Triethylamine (9.09 g, 90 mmol, 3.0 equiv.) was then added. The mixture was cooled to 0°C in an ice bath. p-Toluenesulfonyl chloride (17.16 g, 90 mmol, 3.0 equiv.) was added in portions. The mixture was stirred in an ice bath for 0.5 h. The ice bath was removed and the mixture was stirred at room temperature until the reaction was complete according to TLC analysis. The resulting product system was extracted three times with dichloromethane. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to remove the solvent. The residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 3:1 by volume) to obtain a light yellow solid, compound 24.
[0305] 1H NMR (400MHz, CDCl3) δ8.40(d,J=8.3Hz,2H),8.17(d,J=8.4Hz,2H),7.76(d,J=8.0Hz,2H),7.6 8(d,J=7.6Hz,2H),7.35(t,J=8.4Hz,5H),5.35(d,J=6.9Hz,1H),5.02(d,J=22.7Hz,1H),3.63- 3.35(m,2H),3.37-3.20(m,3H),3.19-2.88(m,3H),2.45(t,J=12.5Hz,8H),1.93-1.74(m,1H), 1.53-1.26(m,4H),1.18(dd,J=14.3,7.1Hz,1H),0.67(q,J=7.5Hz,4H),0.48(t,J=7.3Hz,3H); 13 C NMR (101MHz, CDCl3) δ150.19,146.62,144.43,143.81,136.69,136.57,130.08,129.94,128.58,127.45,1 27.26,124.57,77.48,77.16,76.84,60.04,56.54,49.15,45.33,27.12,25.74,23.54,21.70,11.19,9.85.
[0306] (5) Compound 24 (6.53 g, 10 mmol, 1.0 equiv.), 2,6-dibromomethylpyridine (2.91 g, 11 mmol, 1.1 equiv.), sodium carbonate (4.24 g, 40 mmol, 4.0 equiv.) and DMF (120 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was added to a large amount of water, and a precipitate was precipitated. The precipitate was filtered, and the filter cake was washed with water and dried sequentially to obtain a light yellow solid, compound 25.
[0307] (6) Compound 25 (6.05 g, 8 mmol, 1.0 equiv.) and a mixed acid reagent (50 mL, prepared by mixing glacial acetic acid and 48 wt% hydrobromic acid in a volume ratio of 35:65) were added to a single-necked flask equipped with a stirrer. The mixture was heated to 110°C in an oil bath and reacted for 2 days. The reaction was monitored by HPLC until completion. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain compound 26.
[0308] 1H NMR (400MHz, CDCl3) δ8.09(d,J=8.5Hz,2H),7.81(d,J=8.4Hz,2H),7.53(t,J=7.6Hz,1H),7.06(d,J= 7.5Hz,1H),6.89(d,J=7.6Hz,1H),4.83(d,J=15.1Hz,1H),4.35-4.13(m,1H),4.14-3.97(m,1H),3.7 0-3.49(m,2H),2.69-2.52(m,1H),2.42-2.31(m,3H),2.19(t,J=10.9Hz,2H),1.56(tt,J=13.8,6.9H z,2H),1.36(tt,J=15.1,7.4Hz,1H),1.16-1.07(m,1H),0.93(t,J=7.3Hz,3H),0.87(t,J=7.3Hz,3H); 13 C NMR (101MHz, CDCl3) δ159.59,155.18,149.41,147.38,136.84,128.88,123. 28,120.88,119.59,58.10,51.72,48.96,44.14,25.34,23.83,11.32,11.26.
[0309] (7) Compound 26 (2.24 g, 5 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and acetonitrile (25 mL) was added and stirred to completely dissolve compound 26. Potassium carbonate (6.90 g, 50 mmol, 10.0 equiv.) and ethyl bromoacetate (4.18 g, 25 mmol, 5.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, and the solvent was evaporated from the filtrate under reduced pressure. The residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain a light yellow semisolid compound 27.
[0310] (8) Compound 27 (4.96 g, 8 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by cesium carbonate (20.40 g, 48 mmol, 6.0 equiv.), isopropyl mercaptan (3.66 g, 48 mmol, 6.0 equiv.), and acetonitrile (80 mL). The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was filtered to remove solid insoluble matter, the filtrate was evaporated under reduced pressure to remove the solvent, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain compound 28.
[0311] (9) Compound 28 (1.30 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and methanol (15 mL) was added to completely dissolve compound 28 to obtain a methanol solution of compound 28. Lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 28. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The pH value of the obtained product system was adjusted to 6 with dilute hydrochloric acid, and the mixture was separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 29.
[0312] 1 H NMR (400MHz, D2O) δ7.98(t,J=7.8Hz,1H),7.50(d,J=7.8Hz,1H),7.42(d,J=7.8Hz,1H),4.92(d,J=16. 5Hz,1H),4.65(t,J=16.3Hz,3H),4.10(s,2H),3.75(d,J=18.0Hz,2H),3.58-3.47(m,1H),3.36(t,J=1 8.8Hz,2H),3.29(d,J=11.8Hz,1H),3.01(t,J=10.9Hz,1H),2.65(dd,J=15.0,12.2Hz,1H),2.02-1.81 (m,2H),1.62-1.39(m,1H),1.32(td,J=13.9,7.1Hz,1H),1.07(d,J=7.3Hz,1H),0.89(q,J=7.2Hz,6H); 13 C NMR(101MHz,D2O)δ175.99,169.12,149.31,148.94,140.14,123.02,121.12,60. 58,59.41,58.60,57.67,54.90,54.73,50.21,45.60,20.73,18.10,10.32,8.93.
[0313] (10) Compound 29 (189 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 29. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL6.
[0314] Example 7
[0315] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex MnL7; the reaction formula is as follows:
[0316] (1) Compound 28 (1.74 g, 4 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 28 completely. Potassium carbonate (1.10 g, 8 mmol, 2.0 equiv.) and 4-methoxybenzyl bromide (1.21 g, 6 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain a light yellow semisolid compound 30.
[0317] (2) Compound 30 (1.66 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and then methanol (15 mL) was added to completely dissolve compound 30 to obtain a methanol solution of compound 30; lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 30, stirred at room temperature for 12 h, and monitored by HPLC until the reaction was complete; the resulting product system was adjusted to pH 6 with dilute hydrochloric acid, and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 31.
[0318] 1H NMR (400MHz, D2O) δ7.69(t,J=7.8Hz,1H),7.30(d,J=8.7Hz,2H),7.23(d,J=7.9Hz,1H),6.94(d,J=7.8Hz,1H),6.72(d ,J=8.7Hz,2H),5.09(d,J=16.7Hz,1H),4.65(d,J=16.8Hz,1H),4.55-4.36(m,6H),4.23(d,J=17.1Hz,1H),3.66-3.58( m,5H),3.47(d,J=19.1Hz,2H),3.27-3.15(m,2H),2.86(d,J=9.8Hz,2H),2.07(ddd,J=13.6,7.6,3.1Hz,1H),1.78(dt ,J=13.6,6.7Hz,1H),1.64(ddd,J=13.9,9.5,7.2Hz,1H),1.34-1.17(m,1H),1.11(t,J=7.4Hz,3H),0.96-0.85(m,3H); 13 C NMR(101MHz,D2O)δ175.47,168.71,160.05,149.49,148.25,139.98,132.37,121.31,121.04,114.55 ,64.86,61.70,60.24,58.09,55.32,54.97,54.92,53.80,51.23,46.99,19.56,19.49,10.88,10.31.
[0319] (3) Compound 31 (249 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 31. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at all times and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL7.
[0320] Example 8
[0321] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, and the complex is recorded as MnL8.
[0322] (1) Compound 28 (1.74 g, 4 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 28 completely. Potassium carbonate (1.10 g, 8 mmol, 2.0 equiv.) and 4-phenylbenzyl bromide (1.48 g, 6 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain a light yellow semisolid compound 32.
[0323] (2) Compound 32 (1.80 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and methanol (15 mL) was added to completely dissolve compound 32 to obtain a methanol solution of compound 32. Lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 32. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The pH value of the obtained product system was adjusted to 6 with dilute hydrochloric acid, and the mixture was separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 33.
[0324] 1 H NMR(400MHz,D2O)δ7.46(t,J=7.8Hz,1H),7.38(t,J=6.4Hz,7H),7.31(d,J=7.9Hz,2H),7.08(d,J=7.8Hz,1H),6.80(d ,J=7.7Hz,1H),5.00(d,J=16.7Hz,1H),4.59(d,J=16.8Hz,1H),4.53-4.39(m,4H),4.35(d,J=15.9Hz,1H),4.22(d,J=1 7.1Hz,1H),3.56(ddd,J=49.5,33.7,16.1Hz,4H),3.21(d,J=12.0Hz,2H),2.96-2.73(m,2H),2.07(dd,J=10.6,7.5Hz, 1H),1.77(dt,J=13.4,6.6Hz,1H),1.70-1.55(m,1H),1.32-1.17(m,1H),1.11(t,J=7.3Hz,3H),0.90(t,J=7.3Hz,3H);13 C NMR(101MHz,D2O)δ175.68,168.19,149.37,148.01,141.97,139.85,139.12,131.30,129.05,128.09,127.55,127.26 ,126.71,121.19,121.01,65.64,61.89,60.44,58.01,55.23,55.16,53.39,51.30,47.02,19.69,19.55,10.88,10.34.
[0325] (3) Compound 33 (272 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 33. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at all times and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL8.
[0326] Example 9
[0327] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex MnL9; the reaction formula is as follows:
[0328] (1) Compound 28 (1.74 g, 4 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 28 completely. Potassium carbonate (1.10 g, 8 mmol, 2.0 equiv.) and 4-benzyloxybenzyl bromide (1.66 g, 6 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product was filtered to remove solid insolubles, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain a light yellow semisolid compound 34.
[0329] (2) Compound 34 (1.89 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and methanol (15 mL) was added to completely dissolve compound 34 to obtain a methanol solution of compound 34. Lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 34. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The pH value of the obtained product system was adjusted to 6 with dilute hydrochloric acid, and the mixture was separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 35.
[0330] 1 H NMR(400MHz,D2O)δ7.52(t,J=7.4Hz,1H),7.37(d,J=6.0Hz,3H),7.32-7.27(m,4H),7.05(d,J=7.7Hz,1H),6.83(d,J=7.7Hz ,1H),6.74(d,J=7.5Hz,2H),4.94(q,J=12.0Hz,3H),4.58(d,J=16.7Hz,1H),4.54-4.44(m,2H),4.42-4.31(m,3H),4.23(d,J =17.2Hz,1H),3.74-3.53(m,3H),3.46(t,J=13.2Hz,1H),3.20(d,J=12.6Hz,2H),2.95-2.76(m,2H),2.03(d,J=7.1Hz,1H), 1.79(dt,J=13.0,6.5Hz,1H),1.69-1.56(m,1H),1.27(dt,J=14.2,7.2Hz,1H),1.11(t,J=6.9Hz,3H),0.91(t,J=6.9Hz,3H); 13 C NMR(101MHz,D2O)δ175.74,167.95,159.08,149.35,147.71,139.72,136.28,132.31,128.50,128.06,127.54,121.14,12 0.96,120.70,115.23,69.40,65.54,61.89,60.38,57.84,55.32,55.01,53.21,50.92,46.95,19.71,19.53,10.84,10.30.
[0331] (3) Compound 35 (287 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (5 mL) was then added to completely dissolve compound 35. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at all times and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and lyophilized to obtain a light gray solid powder, which was the complex MnL9.
[0332] Example 10
[0333] Prepare an octa-coordinated Pyclen Gd(III) complex having a structure shown in Formula IV, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, and it is recorded as complex GdL10; the reaction formula is as follows:
[0334] (1) Compound 7 (5.55 g, 10 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (100 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was purified by column chromatography (eluent: dichloromethane:methanol = 10:1 by volume) to obtain compound 36 as a light yellow oil.
[0335] (2) Compound 36 (2.17 g, 5 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 36 completely. Potassium carbonate (1.38 g, 10 mmol, 2.0 equiv.) and methyl 6-bromomethylpicolinate (1.73 g, 7.5 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain a light yellow semisolid compound 37.
[0336] (3) Compound 37 (1.75 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and methanol (15 mL) was added to completely dissolve compound 37 to obtain a methanol solution of compound 37. Lithium hydroxide (0.43 g, 18 mmol, 6.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 37. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The pH value of the obtained product system was adjusted to 6 with dilute hydrochloric acid, and the mixture was separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 38.
[0337] 1 H NMR(400MHz,D2O)δ8.22(dt,J=14.8,7.4Hz,2H),8.03(d,J=7.0Hz,1H),7.97(t,J=7.8Hz,1H),7.55-7.33(m,2H),4.60 (dd,J=16.1,8.5Hz,2H),4.41(t,J=14.0Hz,2H),4.35-4.21(m,1H),3.98(s,1H),3.89(d,J=14.0Hz,1H),3.67(t,J=18. 7Hz,1H),3.40(t,J=19.6Hz,2H),3.13(t,J=13.5Hz,1H),2.99(dd,J=24.9,14.3Hz,2H),2.72(t,J=25.4Hz,1H),2.01(s ,1H),1.79(d,J=36.7Hz,1H),1.54(d,J=42.7Hz,1H),1.29(t,J=19.6Hz,1H),1.07-0.89(m,3H),0.77(t,J=6.9Hz,3H); 13 C NMR(101MHz,D2O)δ169.55,168.77,165.37,153.64,150.21,148.94,146.45,143.20,141.00,129.58,125.80 ,123.19,122.10,66.10,60.00,58.55,57.08,54.82,54.35,53.73,53.67,48.62,19.94,18.37,10.04,9.62.
[0338] (4) Compound 38 (514 mg, 1.0 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (10 mL) was then added to completely dissolve compound 38. GdCl3·6H2O (409 mg, 1.1 mmol, 1.1 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at 100°C for 12 h and monitored by HPLC until the reaction was complete. The pH value of the resulting product system was adjusted to 9.5 using lithium hydroxide solution, centrifuged, and the supernatant was filtered through a 0.22 μm membrane. The filtrate was readjusted to pH 6.5 using dilute hydrochloric acid and lyophilized to obtain a white solid powder, which was the complex GdL10.
[0339] Example 11
[0340] Prepare a Gd(III) complex of octa-coordinated Pyclen having a structure shown in Formula V, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, and it is recorded as complex GdL11; the reaction formula is as follows:
[0341] (1) Compound 17 (2.45 g, 5 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by acetonitrile (30 mL) and stirring to dissolve compound 17 completely. Potassium carbonate (1.38 g, 10 mmol, 2.0 equiv.) and methyl 6-bromomethylpicolinate (1.73 g, 7.5 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product was filtered to remove solid insolubles, the filtrate was evaporated under reduced pressure to remove the solvent, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain a light yellow semisolid, compound 39.
[0342] (2) Compound 39 (640 mg, 1 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (10 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and methanol (5 mL) was added to the residue to dissolve it completely, thereby obtaining a methanol solution of the residue. Lithium hydroxide (48 mg, 2 mmol, 2.0 equiv.) was dissolved in water (5 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of the residue. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The pH value of the obtained product system was adjusted to 6 with dilute hydrochloric acid, and the mixture was separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 40.
[0343] 1 H NMR(400MHz,D2O)δ8.10-6.85(m,6H),5.02-4.77(m,2H),4.67-4.07(m,4H),4.04-2.54(m,10H) ,2.21-1.72(m,2H),1.72-1.29(m,2H),1.06(ddd,J=23.2,14.4,7.0Hz,3H),0.95-0.73(m,3H); 13 C NMR(101MHz,D2O)δ174.06,173.79,173.44,169.01,168.67,166.85,166.64,166.44,150.18,149.93,149.70,149.35,149. 15,149.10,146.93,146.63,140.23,139.90,129.83,128.93,126.81,125.96,125.63,122.95,122.67,122.10,121.38,120. 97,66.74,66.12,64.58,62.23,61.55,60.61,59.75,58.05,57.47,56.77,56.04,55.66,55.38,54.97,54.66,54.16,54.03,53.78,53.54,53.24,52.92,52.27,51.04,50.54,49.34,45.32,20.66,19.42,19.08,18.72,18.36,10.17,9.66,9.61,8.96.
[0344] (3) Compound 40 (257 mg, 0.5 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (10 mL) was then added to completely dissolve compound 40. GdCl3·6H2O (205 mg, 0.55 mmol, 1.1 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at all times and maintained at 6.5. The mixture was stirred at 100°C for 12 h and monitored by HPLC until the reaction was complete. The pH value of the resulting product system was adjusted to 9.5 using lithium hydroxide solution, centrifuged, and the supernatant was filtered through a 0.22 μm membrane. The filtrate was readjusted to pH 6.5 using dilute hydrochloric acid and lyophilized to obtain a white solid powder, complex GdL11.
[0345] Example 12
[0346] Prepare an octa-coordinated Pyclen Gd(III) complex having a structure shown in Formula VI, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, and it is recorded as complex GdL12; the reaction formula is as follows:
[0347] (1) Compound 28 (2.17 g, 5 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 28 completely. Potassium carbonate (1.38 g, 10 mmol, 2.0 equiv.) and methyl 6-bromomethylpicolinate (1.73 g, 7.5 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was separated by column chromatography. The residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain a light yellow semisolid compound 41.
[0348] (2) Compound 41 (1.75 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and methanol (15 mL) was added to completely dissolve compound 41 to obtain a methanol solution of compound 41. Lithium hydroxide (0.43 g, 18 mmol, 6.0 equiv.) was dissolved in water (15 mL), and the lithium hydroxide aqueous solution was added to the methanol solution of compound 41. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The pH value of the obtained product system was adjusted to 6 with dilute hydrochloric acid, and the mixture was separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 42.
[0349] 1 H NMR(400MHz,D2O)δ8.75-6.77(m,6H),5.13-4.78(m,2H),4.65-4.40(m,2H),4 .27(dd,J=42.5,17.0Hz,2H),3.83-3.16(m,8H),3.03-2.79(m,2H),2.17-2.0 0(m,1H),1.79(dt,J=13.4,6.5Hz,1H),1.72-1.50(m,1H),1.23(dt,J=25.7,9 .1Hz,1H),1.16-1.04(m,2H),0.88(dd,J=13.1,6.6Hz,3H),0.82-0.72(m,1H); 13 C NMR(101MHz,D2O)δ175.48,174.32,168.26,167.02,166.70,150.60,149.93,149.57,149.18,148.75 ,147.01,146.83,146.37,141.00,140.10,139.94,129.70,127.55,127.17,125.88,125.32,123.26, 121.85,120.74,69.48,66.53,61.85,61.33,60.63,59.47,59.33,58.88,58.00,57.63,54.87,54.14,53.39,51.98,51.76,50.68,50.56,47.08,19.73,19.39,18.70,17.44,10.81,10.24,10.16,10.01.
[0350] (3) Compound 42 (514 mg, 1.0 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and deionized water (10 mL) was then added to completely dissolve compound 42. GdCl3·6H2O (409 mg, 1.1 mmol, 1.1 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution, and the mixture was stirred at room temperature for 2 h. The pH value was monitored at any time and maintained at 6.5. The mixture was stirred at 100°C for 12 h and monitored by HPLC until the reaction was complete. The pH value of the resulting product system was adjusted to 9.5 using lithium hydroxide solution, centrifuged, and the supernatant was filtered through a 0.22 μm membrane. The filtrate was readjusted to pH 6.5 using dilute hydrochloric acid and lyophilized to obtain a white solid powder, which was the complex GdL12.
[0351] Example 13
[0352] Prepare an octa-coordinated Pyclen Eu(III) complex having a structure shown in Formula IV, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, and the complex is recorded as EuL10; the reaction formula is as follows:
[0353] The complex EuL10 was prepared according to the method of Example 10, except that GdCl3·6H2O (409 mg, 1.1 mmol, 1.1 equiv.) in step (4) of Example 10 was replaced by EuCl3·6H2O (403 mg, 1.1 mmol, 1.1 equiv.).
[0354] Example 14
[0355] Prepare an octa-coordinated Pyclen Yb(III) complex having a structure shown in Formula IV, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, and are recorded as complex YbL10; the reaction formula is as follows:
[0356] The complex YbL10 was prepared according to the method of Example 10, except that GdCl3·6H2O (409 mg, 1.1 mmol, 1.1 equiv.) in step (4) of Example 10 was replaced by YbCl3·6H2O (426 mg, 1.1 mmol, 1.1 equiv.).
[0357] Example 15
[0358] Prepare a Tb(III) complex of octa-coordinated Pyclen having a structure shown in Formula IV, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, and it is recorded as complex TbL10; the reaction formula is as follows:
[0359] The complex TbL10 was prepared according to the method of Example 10, except that GdCl3·6H2O (409 mg, 1.1 mmol, 1.1 equiv.) in step (4) of Example 10 was replaced by TbCl3·6H2O (311 mg, 1.1 mmol, 1.1 equiv.).
[0360] Example 16
[0361] Prepare an octa-coordinated Pyclen Eu(III) complex having a structure shown in Formula V, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, and the complex is recorded as EuL11; the reaction formula is as follows:
[0362] The complex EuL11 was prepared according to the method of Example 11, except that GdCl3·6H2O (205 mg, 0.55 mmol, 1.1 equiv.) in step (3) of Example 11 was replaced by EuCl3·6H2O (202 mg, 0.55 mmol, 1.1 equiv.).
[0363] Example 17
[0364] Prepare an octa-coordinated Pyclen Eu(III) complex having a structure shown in Formula VI, wherein R 1 and R 2 All are -CH2CH3, R" is -H, R"' is -H, recorded as the complex EuL12; the reaction formula is as follows:
[0365] Prepared according to the method of Example 12, the only difference is that GdCl3·6H2O (409 mg, 1.1 mmol, 1.1 equiv.) in step (3) of Example 12 is replaced by EuCl3·6H2O (403 mg, 1.1 mmol, 1.1 equiv.), and the final white solid powder obtained is the complex EuL12.
[0366] Example 18
[0367] Preparation of a hexacoordinated Pyclen Fe(III) complex having a structure shown in Formula I, wherein R 1 and R 2 All are -CH2CH3, R' is -H, R" is -H, and the complex is recorded as FeL1; the reaction formula is as follows:
[0368] The preparation was carried out according to the method of Example 1, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (7) of Example 1 was replaced by FeCl3 (81 mg, 0.5 mmol, 1.0 equiv.). The final light gray solid powder obtained was the complex FeL1.
[0369] Example 19
[0370] Preparation of a hexacoordinated Pyclen Fe(III) complex having a structure shown in Formula I, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as the complex FeL2; the reaction formula is as follows:
[0371] The preparation was carried out according to the method of Example 2, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 2 was replaced by FeCl3 (81 mg, 0.5 mmol, 1.0 equiv.). The light gray solid powder finally obtained was the complex FeL2.
[0372] Example 20
[0373] Preparation of a six-coordinated Pyclen Fe (III) complex having a structure shown in Formula II, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as the complex FeL5; the reaction formula is as follows:
[0374] The preparation was carried out according to the method of Example 5, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 5 was replaced by FeCl3 (81 mg, 0.5 mmol, 1.0 equiv.). The final light gray solid powder obtained was the complex FeL5.
[0375] Example 21
[0376] Prepare a six-coordinated Pyclen Cu (II) complex having a structure shown in Formula II, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as the complex CuL5; the reaction formula is as follows:
[0377] The complex CuL5 was prepared according to the method of Example 5, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 5 was replaced by CuCl2·2H2O (76 mg, 0.5 mmol, 1.0 equiv.). The light gray solid powder finally obtained was the complex CuL5.
[0378] Example 22
[0379] Prepare a six-coordinated Pyclen Co(II) complex having a structure shown in Formula II, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex CoL5; the reaction formula is as follows:
[0380] The complex CoL5 was prepared according to the method of Example 5, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 5 was replaced by CoCl2·6H2O (74 mg, 0.5 mmol, 1.0 equiv.).
[0381] Example 23
[0382] Preparation of a hexacoordinated Pyclen Fe(III) complex having a structure shown in Formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as the complex FeL7; the reaction formula is as follows:
[0383] The preparation was carried out according to the method of Example 7, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 7 was replaced by FeCl3 (81 mg, 0.5 mmol, 1.0 equiv.). The final light gray solid powder obtained was the complex FeL7.
[0384] Example 24
[0385] Prepare a six-coordinated Pyclen Cu(II) complex having a structure shown in formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as the complex CuL7; the reaction formula is as follows:
[0386] The complex CuL7 was prepared according to the method of Example 7, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 7 was replaced by CuCl2·2H2O (76 mg, 0.5 mmol, 1.0 equiv.). The light gray solid powder finally obtained was the complex CuL7.
[0387] Example 25
[0388] Prepare a six-coordinated Pyclen Co(II) complex having a structure shown in formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex CoL7; the reaction formula is as follows:
[0389] The preparation was carried out according to the method of Example 7, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 7 was replaced by CoCl2·6H2O (74 mg, 0.5 mmol, 1.0 equiv.). The final light gray solid powder obtained was the complex CoL7.
[0390] Example 26
[0391] Prepare a Ni(II) complex having a six-coordinated Pyclen structure shown in Formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex NiL7; the reaction formula is as follows:
[0392] The preparation was carried out according to the method of Example 7, except that MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) in step (3) of Example 7 was replaced by NiCl2 (65 mg, 0.5 mmol, 1.0 equiv.). The final light gray solid powder obtained was the complex NiL7.
[0393] Example 27
[0394] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula I, wherein R 1 and R 2 All are -CH3, R' is -H, and R" is -H, which is recorded as the complex MnL13; the reaction formula is as follows:
[0395] (1) Add (R)-2-amino-1-propanol (22.52 g, 300 mmol, 1.0 equiv.) and dichloromethane (180 mL) to a three-necked flask equipped with a mechanical stirrer. After stirring until the solid is completely dissolved, add pyridine (90 mL). Cool the reaction system to 0-5°C in an ice bath. Slowly add p-nitrobenzenesulfonyl chloride (NsCl, 199.46 g, 900 mmol, 3.0 equiv.). Continue to react in an ice bath for 2.0 h. Remove the ice bath. The reaction was stirred at room temperature (25°C) until the reaction was complete as determined by TLC. The resulting product system was extracted three times with dichloromethane, and the organic phases were combined and washed with 2 mol / L hydrochloric acid to remove pyridine. The mixture was then washed with 2 mol / L potassium hydroxide solution, water, and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated to remove the solvent. The residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 5:1, by volume) to obtain compound 1' as a light yellow oil.
[0396] (2) Compound 1' (9.69 g, 40 mmol, 2.0 equiv.) and acetonitrile (100 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred to dissolve completely. Then, p-methoxybenzylamine (2.74 g, 20 mmol, 1.0 equiv.) was added. The reaction solution was heated to 75°C and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 2:1 by volume). The light yellow solid obtained was compound 2'.
[0397] (3) Compound 2' (6.22 g, 10 mmol, 1.0 equiv.), 2,6-dibromomethylpyridine (2.91 g, 11 mmol, 1.1 equiv.), sodium carbonate (4.24 g, 40 mmol, 4.0 equiv.) and N,N-dimethylformamide (DMF, 120 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was added to a large amount of water, and a precipitate was precipitated. The precipitate was filtered, and the filter cake was washed with water and dried in sequence to obtain a light yellow solid, compound 3'.
[0398] (4) Compound 3' (7.25 g, 10 mmol, 1.0 equiv.) and acetonitrile (100 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the entire compound 3'. Cesium carbonate (20.40 g, 48 mmol, 6.0 equiv.) and isopropyl mercaptan (3.66 g, 48 mmol, 6.0 equiv.) were then added and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove the solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain compound 4'.
[0399] (5) Compound 4' (1.77 g, 5 mmol, 1.0 equiv.) and acetonitrile (20 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the compound 4' completely. Potassium carbonate (6.90 g, 50 mmol, 10.0 equiv.) and tert-butyl bromoacetate (4.88 g, 25 mmol, 5.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain compound 5'.
[0400] (6) Compound 5' (436 mg, 1 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (10 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the resulting product system was evaporated under reduced pressure, and the residue was dissolved in 15 mL of water and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain compound 6' as a white solid powder.
[0401] (7) Compound 6' (175 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and then deionized water (5 mL) was added to completely dissolve compound 6'. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution. The mixture was stirred at room temperature for 2 h, and the pH value was monitored at any time. The pH value was maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL13.
[0402] Example 28
[0403] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula I, wherein R 1 and R 2 All are -CH(CH3)2, R' is -H, and R" is -H, which is recorded as complex MnL14; the reaction formula is as follows:
[0404] (1) Add (R)-1-amino-3-methyl-2-butanol (30.95 g, 300 mmol, 1.0 equiv.) and dichloromethane (180 mL) to a three-necked flask equipped with a mechanical stirrer. After stirring until the solid is completely dissolved, add pyridine (90 mL). Cool the reaction system to 0-5°C in an ice bath. Slowly add p-nitrobenzenesulfonyl chloride (NsCl, 199.46 g, 900 mmol, 3.0 equiv.). Continue to react in an ice bath for 2.0 h. Remove the flask. The mixture was stirred in an ice bath and at room temperature (25°C) until the reaction was complete as detected by TLC; the resulting product system was extracted three times with dichloromethane, the organic phases were combined, washed with 2 mol / L hydrochloric acid to remove pyridine, and then washed with 2 mol / L potassium hydroxide solution, water, and saturated brine in that order, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated to remove the solvent. The residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 5:1 by volume) to obtain a light yellow oil, which was compound 1.
[0405] (2) Compound 1" (10.81 g, 40 mmol, 2.0 equiv.) and acetonitrile (100 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred to dissolve them completely. Then, p-methoxybenzylamine (2.74 g, 20 mmol, 1.0 equiv.) was added. The reaction solution was heated to 75°C and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 2:1 by volume). The light yellow solid obtained was compound 2".
[0406] (3) Compound 2" (6.78 g, 10 mmol, 1.0 equiv.), 2,6-dibromomethylpyridine (2.91 g, 11 mmol, 1.1 equiv.), sodium carbonate (4.24 g, 40 mmol, 4.0 equiv.) and N,N-dimethylformamide (DMF, 120 mL) were added sequentially into a three-necked flask equipped with a stirrer and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The obtained product system was added to a large amount of water, and a precipitate was precipitated. The precipitate was filtered, and the filter cake was washed with water and dried in sequence to obtain a light yellow solid, which was compound 3".
[0407] (4) Compound 3" (7.81 g, 10 mmol, 1.0 equiv.) and acetonitrile (100 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the entire compound 3". Cesium carbonate (20.40 g, 48 mmol, 6.0 equiv.) and isopropyl mercaptan (3.66 g, 48 mmol, 6.0 equiv.) were then added and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain compound 4".
[0408] (5) Compound 4" (2.05 g, 5 mmol, 1.0 equiv.) and acetonitrile (20 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the compound 4" completely. Potassium carbonate (6.90 g, 50 mmol, 10.0 equiv.) and tert-butyl bromoacetate (4.88 g, 25 mmol, 5.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The obtained product system was filtered to remove the solid insoluble matter, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain compound 5".
[0409] (6) Compound 5" (492 mg, 1 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (10 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was dissolved in 15 mL of water and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 6".
[0410] (7) Compound 6" (203 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and then deionized water (5 mL) was added to completely dissolve compound 6". MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was added, and the pH value was adjusted to 6.5 using lithium hydroxide solution. The mixture was stirred at room temperature for 2 h, and the pH value was monitored at any time. The pH value was maintained at 6.5, and the mixture was stirred at room temperature for 12 h. HPLC monitoring was performed until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL14.
[0411] Example 29
[0412] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in Formula I, wherein R 1 -CH3, R 2 is -CH(CH3)2, R' is -H, and R" is -H, which is recorded as complex MnL15; the reaction formula is as follows:
[0413] (1) Add (R)-2-amino-1-propanol (22.52 g, 300 mmol, 1.0 equiv.) and dichloromethane (180 mL) to a three-necked flask equipped with a mechanical stirrer. After stirring until the solid is completely dissolved, add pyridine (90 mL). Cool the reaction system to 0-5°C in an ice bath. Slowly add p-nitrobenzenesulfonyl chloride (NsCl, 199.46 g, 900 mmol, 3.0 equiv.). Continue to react in an ice bath for 2.0 h. Remove the ice bath. The reaction was stirred at room temperature (25°C) until the reaction was complete as determined by TLC. The resulting product system was extracted three times with dichloromethane, and the organic phases were combined and washed with 2 mol / L hydrochloric acid to remove pyridine. The mixture was then washed with 2 mol / L potassium hydroxide solution, water, and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated to remove the solvent. The residue was purified by column chromatography (the eluent used was petroleum ether:ethyl acetate = 5:1, by volume) to obtain compound 1' as a light yellow oil.
[0414] (2) Compound 1' (9.69 g, 40 mmol, 2.0 equiv.) and acetonitrile (100 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred to dissolve them completely. Then, p-methoxybenzylamine (5.48 g, 40 mmol, 1.0 equiv.) was added and the reaction solution was heated to 75°C and monitored by HPLC until the reaction was complete. Then, compound 1" (10.81 g, 40 mmol, 2.0 equiv.) was added and reacted at 75°C and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure and the residue was purified by column chromatography (the eluent used was petroleum ether: ethyl acetate = 2:1 by volume). The light yellow solid obtained was compound 2"'.
[0415] (3) Compound 2'' (6.49 g, 10 mmol, 1.0 equiv.), 2,6-dibromomethylpyridine (2.91 g, 11 mmol, 1.1 equiv.), sodium carbonate (4.24 g, 40 mmol, 4.0 equiv.) and N,N-dimethylformamide (DMF, 120 mL) were added sequentially to a three-necked flask equipped with a stirrer and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was added to a large amount of water, and a precipitate was precipitated. The precipitate was filtered, and the filter cake was washed with water and dried in sequence to obtain a light yellow solid, compound 3''.
[0416] (4) Compound 3"' (7.53 g, 10 mmol, 1.0 equiv.) and acetonitrile (100 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the entire compound 3"'. Cesium carbonate (20.40 g, 48 mmol, 6.0 equiv.) and isopropyl mercaptan (3.66 g, 48 mmol, 6.0 equiv.) were then added and stirred at room temperature for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the filtrate was evaporated to remove the solvent under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain compound 4"'.
[0417] (5) Compound 4'' (1.91 g, 5 mmol, 1.0 equiv.) and acetonitrile (20 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve the compound 4'' completely. Potassium carbonate (6.90 g, 50 mmol, 10.0 equiv.) and tert-butyl bromoacetate (4.88 g, 25 mmol, 5.0 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the filtrate was evaporated under reduced pressure to remove the solvent, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 5:1 by volume) to obtain compound 5''.
[0418] (6) Compound 5'' (611 mg, 1 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, followed by trifluoroacetic acid (10 mL). The mixture was heated to 90°C in an oil bath and monitored by HPLC until the reaction was complete. The solvent of the obtained product system was evaporated under reduced pressure, and the residue was dissolved in 15 mL of water and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain compound 6'' as a white solid powder.
[0419] (7) Compound 6'' (189 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer, and then deionized water (5 mL) was added to completely dissolve compound 6''. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH value was adjusted to 6.5 using lithium hydroxide solution. The mixture was stirred at room temperature for 2 h, and the pH value was monitored at any time. The pH value was maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product system was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and freeze-dried to obtain a light gray solid powder, which was the complex MnL15.
[0420] Example 30
[0421] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex MnL16; the reaction formula is as follows:
[0422] (1) Compound 28 (1.74 g, 4 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 28 completely. Potassium carbonate (1.10 g, 8 mmol, 2.0 equiv.) and 1-bromobutane (822 mg, 6 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product was filtered to remove solid insolubles, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain a light yellow semisolid compound 43.
[0423] (2) Compound 43 (1.47 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and methanol (15 mL) was added to completely dissolve compound 43 to obtain a methanol solution of compound 43; lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 43, stirred at room temperature for 12 h, and monitored by HPLC until the reaction was complete; the resulting product system was adjusted to pH 6 with dilute hydrochloric acid, and separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder as compound 44.
[0424] (3) Compound 44 (217 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer. Deionized water (5 mL) was then added to dissolve compound 44 completely. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH was adjusted to 6.5 with lithium hydroxide solution. The mixture was stirred at room temperature for 2 h, and the pH was monitored at all times. The pH was maintained at 6.5 and stirred at room temperature for 12 h. HPLC monitoring was performed until the reaction was complete. The resulting product was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and lyophilized to obtain a light gray solid powder, the complex MnL16. m / z: 487.20 (ESI-MS), calculated: 487.21.
[0425] Example 31
[0426] Prepare a six-coordinated Pyclen Mn (II) complex having a structure shown in formula III, wherein R 1 and R 2 All are -CH2CH3, R' is R″ is -H, recorded as complex MnL17; the reaction formula is as follows:
[0427] (1) Compound 28 (1.74 g, 4 mmol, 1.0 equiv.) and acetonitrile (30 mL) were added to a single-necked flask equipped with a stirrer and stirred to dissolve compound 28 completely. Potassium carbonate (1.10 g, 8 mmol, 2.0 equiv.) and diethylene glycol-2-bromoethyl methyl ether (1.36 g, 6 mmol, 1.5 equiv.) were then added in sequence. The mixture was heated to 50°C in an oil bath and stirred for 12 h. The reaction was monitored by HPLC until completion. The resulting product system was filtered to remove solid insoluble matter, the solvent was evaporated from the filtrate under reduced pressure, and the residue was purified by column chromatography (the eluent used was dichloromethane:methanol = 10:1 by volume) to obtain a light yellow semisolid compound 45.
[0428] (2) Compound 45 (1.74 g, 3 mmol, 1.0 equiv.) was added to a single-necked flask equipped with a stirrer, and methanol (15 mL) was added to completely dissolve compound 45 to obtain a methanol solution of compound 45. Lithium hydroxide (0.29 g, 12 mmol, 4.0 equiv.) was dissolved in water (15 mL), and the obtained lithium hydroxide aqueous solution was added to the methanol solution of compound 45. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The pH value of the obtained product system was adjusted to 6 with dilute hydrochloric acid, and the mixture was separated by semi-preparative HPLC. The separated liquid phases were combined, and acetonitrile (from the mobile phase in the semi-preparative HPLC) and part of the water were removed under reduced pressure. The remaining liquid was lyophilized to obtain a white solid powder, which was compound 46.
[0429] (3) Compound 46 (262 mg, 0.5 mmol, 1.05 equiv.) was added to a single-necked flask equipped with a stirrer. Deionized water (5 mL) was then added to dissolve compound 46 completely. MnCl2·4H2O (94 mg, 0.476 mmol, 1.0 equiv.) was then added. The pH was adjusted to 6.5 with lithium hydroxide solution and stirred at room temperature for 2 h. The pH was monitored at all times and maintained at 6.5. The mixture was stirred at room temperature for 12 h and monitored by HPLC until the reaction was complete. The resulting product was centrifuged, and the supernatant was filtered through a 0.22 μm membrane and lyophilized to obtain a light gray solid powder, the complex MnL17. m / z: 577.20 (ESI-MS), calculated: 577.24.
[0430] Test Example 1
[0431] In this test example, the relaxation rate parameters of some Pyclen complexes in the embodiments of the present invention were measured using a 1.5T nuclear magnetic resonance spectrometer and compared with those of a seven-coordinated Mn-based complex. The specific results are shown in Table 1. The structure of the seven-coordinated Mn-based complex is shown below:
[0432] Table 1 Relaxation rate parameters of seven-coordinated Mn-based complexes and Pyclen complexes MnL1 to MnL9 of the present invention
[0433] As shown in Table 1, because the ligands PCTA, X-PCTA-1, and X-PCTA-2 are seven-coordinate ligands, the number of inner-layer coordinated water molecules in the complexes they form with Mn(II) is zero, resulting in extremely low r1 and r2 values, which remain essentially unchanged after the addition of HSA. The hexacoordinated Pyclen complexes MnL1, MnL4, and MnL6 provided by the present invention show little change in r1 and r2 values before and after the addition of HSA. However, after the introduction of 4-methoxybenzyl (PMB) into these complexes, significant HSA binding is demonstrated. When the more lipophilic 4-benzyloxybenzyl (BnOBn) or 4-phenylbenzyl (BP) is introduced, these Mn-based metal complexes exhibit extremely strong binding to HSA, with the binding capacity increasing by nearly 3-fold.
[0434] Test Example 2
[0435] Lipophilicity is a property that can significantly influence a compound's pharmacological activities, including absorption, distribution, metabolism, excretion, and toxicity. In this example, the oil-water distribution coefficient (LogP) of some Pyclen complexes was determined. Specifically, the retention times of a series of compounds with known LogP values were measured using reversed-phase high-performance liquid chromatography. Several Pyclen complexes were then tested using the same method. The results are shown in Table 2.
[0436] Table 2 LogP of some Pyclen complexes in the present invention
[0437] Liver uptake and blood clearance rates are directly related to the LogP value. The Pyclen complex centers in Table 2 are all coupled with a fat-soluble group (BP or PMB), and the LogP values can all reach above 1.0.
[0438] Test Example 3
[0439] This test example tests the stability of some Pyclen complexes. Specifically, the stability of the compounds in an acidic solution at pH = 1 is detected by high performance liquid chromatography. The complexes GdL10, GdL11, and GdL12 prepared in the examples of the present invention are dissolved in an acidic aqueous solution at pH = 1 and placed at room temperature (298K, 25°C). The decay of the above compounds over time is then tested by high performance liquid chromatography, and the half-life time (t 1 / 2 ), where the half-life of promecine (Gd-DOTA) is reported in the literature. Specific results are shown in Table 3. As shown in Table 3, the Gd(III) complexes provided by the present invention have high stability, significantly higher than promecine, among which the complex GdL12 has the highest stability.
[0440] Table 3 Comparison of the stability of Prumetin and some Gd-based complexes in the present invention
[0441] Test Example 4
[0442] This test example examined the spectral properties of some pyclen complexes in aqueous solution using fluorescence emission spectrometry and UV-visible absorption spectrometry. Figure 1 shows the UV absorption and fluorescence emission spectra of the complex EuL10 prepared in Example 13. Figure 2 shows the UV absorption and fluorescence emission spectra of the complex EuL11 prepared in Example 16. As shown in Figures 1 and 2, both EuL10 and Eu11 have maximum UV absorption near 270 nm and exhibit characteristic emission bands of the rare earth metal Eu in their fluorescence emission spectra.
[0443] Test Example 5
[0444] This test case tests the performance of some Pyclen complexes as MRI contrast agents, as follows:
[0445] Prepare 0.1mol / L PBS buffer with pH=7.4, weigh a certain amount of the sample to be tested and dissolve it in the PBS buffer to prepare a 50mmol / L stock solution for use. The normal mice and tumor-bearing mice used in the experiment were BALB / c nude mice. The 4T1 cell suspension was subcutaneously injected into the right hind limb of the mice. The tumor volume was observed within 3 to 6 days after injection. When the volume reached 50 to 150 mm 3 The device can be used for animal imaging. The anesthetic is 0.3% sodium pentobarbital, injected intraperitoneally at a dose of 50-60 mg / kg. The contrast agent is injected at a dose of 0.1 mmol / kg through the tail vein. Mice are imaged at different time points after drug injection.
[0446] Figure 3 shows the complex MnL1 prepared in Example 1 as an MRI contrast agent for imaging subcutaneous tumor-bearing mice. As shown in Figure 3, the complex MnL1 can better distinguish between tumor sites and normal tissues.
[0447] Figure 4 shows the image of the complex MnL2 prepared in Example 2 as an MRI contrast agent for imaging subcutaneous tumor-bearing mice. As shown in Figure 4, the complex MnL2 can better distinguish between tumor sites and normal tissues.
[0448] Figure 5 shows the complex MnL4 prepared in Example 4 used as an MRI contrast agent for liver and gallbladder imaging in mice. As shown in Figure 5, the complex MnL4 has a certain liver and gallbladder targeting ability.
[0449] Figure 6 shows the complex MnL5 prepared in Example 5 used as an MRI contrast agent for hepatobiliary imaging in mice. As shown in Figure 6, the complex MnL5 has good hepatobiliary targeting ability and can be used for hepatobiliary imaging.
[0450] Figure 7 shows the complex GdL10 prepared in Example 10 as an MRI contrast agent for imaging subcutaneous tumor-bearing mice. As shown in Figure 7, the complex MnL10 can better distinguish between tumor sites and normal tissues.
[0451] Figure 8 shows the complex MnL13 prepared in Example 27 as an MRI contrast agent for imaging subcutaneous tumor-bearing mice. As shown in Figure 8, the complex MnL13 can well distinguish between tumor sites and normal tissues.
[0452] Figure 9 shows the MRI contrast agent used for imaging of subcutaneous tumor-bearing mice using the complex MnL14 prepared in Example 28. As shown in Figure 9, the complex MnL14 can effectively distinguish between tumor sites and normal tissues.
[0453] Figure 10 shows the MRI contrast agent used for imaging of subcutaneous tumor-bearing mice using the complex MnL15 prepared in Example 29. As shown in Figure 10, the complex MnL15 can effectively distinguish between tumor sites and normal tissues.
[0454] Figure 11 shows the complex MnL17 prepared in Example 31 as an MRI contrast agent for imaging subcutaneous tumor-bearing mice. As shown in Figure 11, the complex MnL17 can well distinguish between tumor sites and normal tissues.
[0455] As shown in the above test examples, when the Pyclen ligands provided by the present invention introduce lipophilic groups, their Mn-based metal complexes exhibit extremely strong binding ability with HSA and have certain hepatobiliary targeting capabilities. They show good imaging effects in MRI imaging of subcutaneous tumor mice, with imaging capabilities comparable to or superior to those of Gd-DOTA.
[0456] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. A Pyclen ligand having a structure shown in any one of formulas i to vi: In the formulas i to vi, R 1 and R 2 are independently -H, C1-C4 alkyl, -CH2OH, -CH(CH3)OH, -CH2CH2OH, -(CH2)3NH2 or -(CH2) n Ph, n=1-4; In the formulas i to iii, R' is -H, The X is -CH2-, -NH- or -O-, and the m=1 to 10; R″ in the formulas i to vi is -H, halogen, -COOH, -NO2, -CF3, -C(CH3)3, -Ph or -OBn; R″′ in the formulas iv to vi is -H, halogen, -COOH, -NO2, -CF3, -C(CH3)3, -Ph or -OBn.
2. The Pyclen ligand according to claim 1, characterized in that The C1-C4 alkyl group is -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3 or -CH2CH2CH2CH3.
3. The Pyclen ligand according to claim 2, characterized in that In the formulas i to vi, R 1 and R 2 are -CH3, -CH2CH3 or -CH(CH3)2; or R 1 is -CH3 and R 2 It is -CH(CH3)2.
4. The Pyclen ligand according to claim 1, characterized in that Said for 5. The Pyclen ligand according to any one of claims 1 to 4, characterized in that The Pyclen ligand is any one of the following compounds:
6. The method for preparing the Pyclen ligand according to any one of claims 1 to 5, characterized in that: (1-1) When R′ in formula (i) is -H, the preparation method of the Pyclen ligand having the structure shown in formula (i) comprises the following steps: Compound a, tert-butyl bromoacetate, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound a-1; The compound a-1 is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula i; The structural formulas of compound a and compound a-1 are shown below: The R 1 , R 2 and R″ are as defined in formula i; (1-2) When R′ in formula (i) is not -H, the preparation method of the Pyclen ligand having the structure shown in formula (i) comprises the following steps: Compound b, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound b-1; The compound b-1, lithium hydroxide, methanol and water are mixed to carry out a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula i; The structural formulas of the compound b and compound b-1 are shown below: The R 1 , R 2 , R′ and R″ are as defined in formula i; (2-1) When R′ in formula ii is not -H, the preparation method of the Pyclen ligand having the structure shown in formula ii comprises the following steps: Compound c, R′-Br, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound c-1; The compound c-1 is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula ii; The structural formulas of compound c and compound c-1 are shown below: The R 1 , R 2 , R′ and R″ are as defined in formula ii; (2-2) When R′ in formula ii is -H, the preparation method of the Pyclen ligand having the structure shown in formula ii comprises the following steps: Compound c is mixed with trifluoroacetic acid and subjected to a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula ii; (3-1) When R′ in formula iii is not -H, the preparation method of the Pyclen ligand having the structure shown in formula iii comprises the following steps: Compound d, R′-Br, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound d-1; The compound d-1, lithium hydroxide, methanol and water are mixed to carry out a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula iii; The structural formulas of the compound d and the compound d-1 are shown below: The R 1 , R 2 , R′ and R″ are as defined in formula iii; (3-2) When R′ in formula iii is -H, the preparation method of the Pyclen ligand having the structure shown in formula iii comprises the following steps: Compound d, lithium hydroxide, methanol and water are mixed to perform a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula iii; (4) A method for preparing a Pyclen ligand having a structure shown in Formula IV, comprising the following steps: Compound a, ethyl bromoacetate, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound a-2; The compound a-2 is mixed with trifluoroacetic acid and subjected to a deprotection reaction to obtain a compound a-3; The compound a-3, compound a-4, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound a-5; The compound a-5, lithium hydroxide, methanol and water are mixed to perform a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula iv; The structural formulas of the compounds a-2, a-3, a-4 and a-5 are shown below: The R 1 , R 2 , R″ and R″′ are as defined in formula iv; (5) A method for preparing a Pyclen ligand having a structure shown in Formula V, comprising the following steps: Compound c, compound a-4, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound c-2; The compound c-2 is mixed with trifluoroacetic acid to carry out a first-stage hydrolysis reaction to obtain a hydrolysis intermediate; The hydrolysis intermediate, lithium hydroxide, methanol and water are mixed to carry out a second-stage hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula v; The structural formula of the compound c-2 is shown below: The R 1 , R 2 , R″ and R″′ are as defined in formula v; (6) A method for preparing a Pyclen ligand having a structure shown in Formula VI, comprising the following steps: Compound d, compound a-4, potassium carbonate and acetonitrile are mixed to carry out a nucleophilic substitution reaction to obtain compound d-2; The compound d-2, lithium hydroxide, methanol and water are mixed to perform a hydrolysis reaction to obtain a Pyclen ligand having a structure shown in formula vi; The structural formula of the compound d-2 is shown below: The R 1 , R 2 , R″ and R″′ are as defined in formula vi.
7. The preparation method according to claim 6, characterized in that: The temperature of the nucleophilic substitution reaction in (1-1) is 45-55°C and the time is 10-15h; the temperature of the hydrolysis reaction is 85-95°C.
8. The preparation method according to claim 6, characterized in that: The temperature of the nucleophilic substitution reaction in (1-2) is 45-55°C and the time is 10-15h; the temperature of the hydrolysis reaction is 15-35°C and the time is 10-15h.
9. The preparation method according to claim 6, characterized in that: The temperature of the nucleophilic substitution reaction in (2-1) is 45-55°C and the time is 10-15h; the temperature of the hydrolysis reaction is 85-95°C.
10. The preparation method according to claim 6, characterized in that: The temperature of the hydrolysis reaction in (2-2) is 85-95°C.
11. The preparation method according to claim 6, characterized in that: The temperature of the nucleophilic substitution reaction in (3-1) is 45-55°C and the time is 10-15h; the temperature of the hydrolysis reaction is 15-35°C and the time is 10-15h.
12. The preparation method according to claim 6, characterized in that: The temperature of the hydrolysis reaction in (3-2) is 15 to 35° C. and the time is 10 to 15 hours.
13. The preparation method according to claim 6, characterized in that: The temperature of the nucleophilic substitution reaction in preparing compound a-2 in (4) is 45-55°C, and the time is 10-15h; the temperature of the deprotection reaction is 85-95°C; the temperature of the nucleophilic substitution reaction in preparing compound a-5 is 45-55°C, and the time is 10-15h; the temperature of the hydrolysis reaction is 15-35°C, and the time is 10-15h.
14. The preparation method according to claim 6, characterized in that: The temperature of the nucleophilic substitution reaction in (5) is 45-55°C and the time is 10-15h; the temperature of the first stage hydrolysis reaction is 85-95°C; the temperature of the second stage hydrolysis reaction is 15-35°C and the time is 10-15h.
15. The preparation method according to claim 6, characterized in that: The temperature of the nucleophilic substitution reaction in (6) is 45-55°C and the time is 10-15h; the temperature of the hydrolysis reaction is 15-35°C and the time is 10-15h.
16. A Pyclen complex having a structure shown in any one of Formulas I to VI: In the formulas I to VI, R 1 and R 2 , R′ in formulas I to III, R″ in formulas I to VI, and R″′ in formulas IV to VI are as defined in claim 1 or 2; In the formulas I to III, M1 is Mn(II), Fe(III), Co(II), Cu(II) or Ni(II); In the formulas IV to VI, M2 is a lanthanide metal ion.
17. The Pyclen complex according to claim 16, characterized in that The M2 is Gd(III), Eu(III), Tb(III) or Yb(III).
18. The Pyclen complex according to claim 16 or 17, characterized in that The Pyclen complex is any one of the following compounds:
19. A method for preparing the Pyclen complex according to any one of claims 16 to 18, comprising the following steps: A Pyclen ligand, a soluble metal salt and water are mixed to carry out a complexation reaction to obtain a Pyclen complex having a structure shown in any one of Formulas I to VI; the Pyclen ligand is the Pyclen ligand described in any one of Claims 1 to 5; and the metal ion in the soluble metal salt is M1 or M2.
20. The preparation method according to claim 19, characterized in that: The soluble metal salt is hydrochloride.
21. The preparation method according to claim 20, characterized in that: The hydrochloride is FeCl3, NiCl2, CuCl2·2H2O, CoCl2·6H2O, MnCl2·4H2O, GdCl3·6H2O, EuCl3·6H2O, YbCl3·6H2O or TbCl3·6H2O.
22. The preparation method according to claim 19, characterized in that: When the Pyclen ligand is a compound of formula i to iii, the temperature of the complex reaction is room temperature and the time is 8 to 24 hours; when the Pyclen ligand is a compound of formula iv to vi, the temperature of the complex reaction is 90 to 110° C. and the time is 8 to 24 hours.
23. A pharmaceutical composition, characterized in that The invention comprises the Pyclen complex according to any one of claims 16 to 18 and a pharmaceutically acceptable carrier.
24. Use of the Pyclen complex according to any one of claims 16 to 18 or the pharmaceutical composition according to claim 23 in the preparation of a magnetic resonance imaging contrast agent.
25. The use according to claim 24, characterized in that The magnetic resonance imaging contrast agent is a magnetic resonance imaging contrast agent targeting the liver and gallbladder.
26. A magnetic resonance imaging contrast agent, characterized in that: The invention comprises the Pyclen complex according to any one of claims 16 to 18 or the pharmaceutical composition according to claim 23.
Citation Information
Patent Citations
Macrocyclic ligands with picolinate group(s), complexes thereof and also medical uses thereof
CN108884095A
Chiral 1, 4, 7, 10-tetraaza-2, 6-pyridine cyclophane derivative and preparation and application of metal chelate of chiral 1, 4, 7, 10-tetraaza-2, 6-pyridine cyclophane derivative
CN114105983A
Actinium-225 complexes and conjugates for targeted radiotherapy
WO2002067999A2
Tissue-specific manganese based MRI contrast agents
WO2023122564A2
Cited By
Method for constructing planar chiral [2, 2] paracyclophane through cobalt-catalyzed asymmetric carbon-hydrogen bond activation-kinetic resolution
CN119530825A
A method for constructing facially chiral [2,2]paracyclophanes by cobalt-catalyzed asymmetric carbon-hydrogen bond activation-kinetic resolution
CN119530825B
